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ABSTRACT 
 
 
III 
 
HIV-1 integrase is an essential enzyme in the HIV replication cycle and is a 
validated target for antiretroviral drugs. Due to the inevitable emergence of drug 
resistance of HIV-1 strains to all currently approved FDA antiretroviral drugs, 
antivirals with new mechanisms of action are continuously investigated. As such, 
this study aimed to reposition existing drugs as HIV-1 integrase inhibitors by 
screening the NIH Clinical Collection compound library comprising 727 
compounds. Recombinant integrase was expressed in bacterial cells, purified by 
nickel affinity chromatography, and used to set up a Scintillation Proximity Assay 
(SPA). The SPA was subsequently amended to an automated system to allow for 
rapid screening of compounds. The complete compound library was successfully 
screened using the newly established automated SPA. Overall, only two 
compounds were identified as HIV-1 IN inhibitors: cefixime trihydrate and a 
previously identified HIV integrase inhibitor, epigallocatechin gallate. These 
compounds exerted IC50 values < 10µM in the automated SPA. Cefixime 
trihydrate was not toxic to mammalian cells (CC50 > 200µM) while no appreciable 
antiretroviral activity was observed in in vitro phenotypic inhibition assays (23% 
inhibition of viral replication), thus concluding that this compound was non-
selective. By contrast, epigallocatechin gallate was toxic to mammalian cells at 
the evaluated ranges (CC50 = 23 + 1µM) and therefore could not be validated as 
an integrase inhibitor in in vitro phenotypic inhibition assays. Overall, this study 
resulted in the establishment of an automated SPA, the successful screening of 
727 compounds, and the availability of a platform to expedite the future screening 
of potential HIV-1 integrase inhibitors.   
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CHAPTER 1 
Introduction 
 
1 
 
1.1. HIV/AIDS overview 
1.1.1. History of HIV/AIDS 
The human immunodeficiency virus (HIV) is a retrovirus that attacks and destroys 
the immune system by infecting vital cells in the immune defence system such as 
T-lymphocytes, more specifically CD4+ T-lymphocytes, and ultimately progresses 
to acquired immunodeficiency syndrome (AIDS).1–3 HIV/AIDS was recognised in 
the 1980’s however the first confirmed mortality attributed to HIV/AIDS is believed 
to have occurred in 1959 when a Congolese man died from a mysterious illness.4 
In 1986, preserved blood samples obtained from this man revealed that he was 
infected with HIV.4 AIDS was first recognised in 1981 in the United States of 
America (USA) when an outbreak of rare infections associated with the immune 
system such as Kaposi’s sarcoma (KS) and Pneumocystis carinii pneumonia 
(PCP) emerged among gay men.5–7 The Centers for Disease Control (CDC) 
reported this illness as gay-related immune deficiency (GRID).5 In 1982, this 
disease was then observed in heterosexuals, individuals who received blood 
transfusions and drug addicts which indicated that HIV/AIDS was not restricted to 
homosexuals.8 The CDC subsequently termed this deadly disease AIDS since 
the major opportunistic infections, PCP and KS, only occurs in individuals’ with 
weak immune systems. In 1984, the Pasteur Institute isolated a retrovirus 
lymphadenopathy virus (LAV) believed to be the causative agent of AIDS.1 
However, in 1984 Gallo and co-workers3 reported the isolation of human T-
lymphotropic virus (HTLV-III) which was also responsible for HIV/AIDS. LAV and 
HTLV-III were identified as the same virus and was named HIV in 1986. At this 
point, HIV/AIDS was found to be disseminated across at least 33 countries.9 The 
first HIV treatment, azidothymidine (AZT), was approved by the Food and Drug 
Administration (FDA) in 1987.10  
1.1.2. Epidemiology and phylogeny of HIV/AIDS 
In 2012, it was estimated that 35.3 million people were infected with HIV.11 Sub-
Saharan Africa is the region most affected by HIV with 25 million infected 
people.11 Of these, 6.1 million HIV infected people are living in South Africa, the 
country with the highest number of HIV infections across the world.11 Although 
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HIV incidence levels have reduced by 42% in South Africa, the epidemic 
persists.11  
HIV is believed to have originated from multiple cross-species transmission of the 
simian immunodeficiency virus (SIV) infecting non-human primates in Sub-
Saharan Africa.12–15 HIV is characterized into HIV type 1 (HIV-1) and HIV type 2 
(HIV-2).16,17 HIV-1, the more infectious strain, is derived from SIV that naturally 
occur in chimpanzees (SIVcpz) and gorillas (SIVgor).13,18 SIVcpz is classified into 
SIVcpz Pan troglodytes troglodytes (Ptt) and SIVcpz Pan troglodytes 
schweinfurthii (Pts) based on their sub-species lineages.19 The SIVcpzPtt and 
SIVcpzPts lineages resulted in viruses that differ by 30-50% in the viral gag, pol 
and env sequences.20 HIV-2 derived from SIV in sooty mangabey monkeys 
(SIVsmm).19,21,22 
HIV belongs to the Retroviridae family and falls within the Lentivirus genus as it 
consists of single stranded positive-sense RNA that is reverse transcribed by a 
virally encoded reverse transcriptase (RT).23,24 Phylogeny analysis of the HIV 
Lentivirus have elucidated the geographic location of the HIV-1 and HIV-2 
transmission across species. HIV-1 comprises four groups that are a result of 
distinct cross-species transmissions: M (Major), O (Outlier), N (Non M or Non O) 
and P.25,26 Group M is the most predominant group and is responsible for almost 
90% of HIV infections globally.27 Group O is less prevalent than Group M and is 
responsible for only 1% of HIV infections and is confined to Cameroon, Gabon 
and neighbouring countries.28,29 Only 13 cases of Group N infection have thus far 
been reported and they were restricted to infected individuals in Cameroon.30 
Group P, the most recently identified group, was documented in only two infected 
individuals from Cameroon.27,31 All four groups of HIV-1, derived from SIVcpz, as 
well as the SIVgor strain, cluster with the SIVcpzPtt lineage which infers that this 
subspecies was the original reservoir for human and gorilla infections.32 Group M 
and N are believed to have originated from chimpanzees in the south-eastern 
corner of Cameroon and south-central Cameroon, respectively.18,33 Group P is 
derived from the SIVgor lineage whereas the origin of Group O is not known 
since it is not closely related to ape viruses and hence could originate from either 
chimpanzees or gorillas.32 Group M comprise subtypes A (A1, A2, A3), B, C, D, 
F(F1, F2), G, H, J and K that represent different HIV lineages, geographical and 
phylogenetic associations.34,35 The migration pathways of these subtypes have 
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been described. Subtype A and D originated in central Africa and established in 
eastern Africa.36 Subtype B is believed to have originated from a single African 
strain that spread to Haiti and ultimately into America and Europe.36 HIV-1 
subtype C is responsible for most HIV infections and is predominant across 
Southern- and East Africa as well as India.35,37 Subtype F is prevalent in central 
Africa, eastern Europe and South America whereas subtype G is prevalent in 
West- and East Africa and central Europe.38 Subtype H has been observed in 
central Africa whereas subtype K has been observed in the Democratic Republic 
of Congo and Cameroon.38 Subtype J is only prevalent in central America.38 Inter-
subtype recombination is the result of co-infection with at least two different 
subtypes. When this occurs in only one individual, it is known as a unique 
recombinant form (URF). Upon transmission of a URF in many individuals that 
are not epidemiologically related, it is known as a circulating recombinant form 
(CRF). There are currently 51 CRFs characterized within the HIV-1 group M.34 
HIV-2 is less prevalent than HIV-1 and is mainly confined to West-Africa.39 Thus 
far, eight distinct HIV-2 lineages (A-H) have been identified that originated from 
independent host transmissions.40,41 HIV-2 is less infectious than HIV-1 and the 
number of infection caused by HIV-2 is declining, presumably due to its low viral 
load.42,43    
1.1.3. The HIV-1 virion and its genomic organization  
The HIV-1 virus particle (virion) is sphere shaped with a diameter of 90 to 100 
nanometer (nm).3,44 Figure 1.1 illustrates the three basic structures of the HIV 
virion: the viral envelope, HIV matrix proteins and the viral capsid. The viral 
envelope consists of a double lipid layer, formed upon budding of the capsid from 
the host cell, surrounded by 72 protrusions comprised of trimeric glycoproteins 
(Gp) 120 attached to a trimeric transmembrane Gp41 stem.8,17,18 The matrix 
comprises p17 proteins and is found between the viral envelope and viral core. 
The conical viral core consists of p24 proteins that encapsulate the viral genetic 
material, two copies of non-covalently linked single RNA positive strands, and 
essential viral replication enzymes such as RT, integrase (IN) and protease 
(PR).47,48 
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Figure 1.1: The structure and constituents of the HIV virus particle (virion). The illustration 
depicts the viral RNA genome and viral enzymes contained in a p24 viral core. The p24 viral core is 
then surrounded by the p17 matrix and the viral envelope. The viral envelope contains the 
transmembrane glycoprotein (gp) 41 stem attached to the surface gp120, arranged as trimers. 
Adapted and modified from www.stanford.edu/group/virus, accessed 1/09/2013.
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The HIV genome consists of only nine genes: gag, pol, env, tat, rev, nef, vif, vpr 
and vpu depicted in Figure 1.2. The gag and env genes encode structurally 
related proteins, Gag and envelope glycoproteins (gp160) that are required to 
produce new virus particles. The Gag polyprotein is cleaved by the viral PR into 
smaller structural proteins such as p17, p24 and the nucleocapsid (p9).50 Cellular 
PR cleave gp160 into the transmembrane gp41 and the surface gp120.51 The pol 
gene encodes polymerase enzymes RT, RNAse H, IN and PR that are expressed 
as a Gag-Pol fusion protein (Figure 1.2). The virally encoded PR then cleaves the 
Pol polypeptide from the Gag-Pol fusion protein where the Pol peptide is 
subsequently digested further into RT, RNAse H, IN and PR that are responsible 
for DNA synthesis, viral DNA integration into host DNA and the cleavage of Gag-
Pol polyproteins during maturation of virions, respectively.52–54 The regulatory 
genes tat and rev encodes the transcription transactivator (Tat) and regulatory 
factor (Rev), respectively and aid in regulating viral replication. Tat is an RNA 
binding protein that binds to the transactivation response element (TAR) at the 5’ 
terminal end of HIV RNA thereby activating transcription.55 Rev is a sequence 
based RNA binding protein that regulates HIV gene expression by binding to a 
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complex RNA secondary structure, termed the Rev Response Element (RRE), 
subsequently facilitating the migration of unspliced or incomplete spliced viral 
RNA from the nucleus to the cytoplasm.56–58 Accessory genes nef, vif, vpr and 
vpu encode the virulence factors negative factor (Nef), viral infectivity factor (Vif), 
viral protein R (Vpr) and viral protein U (Vpu), respectively.47,48,59,60 These 
proteins while not essential for viral replication in vitro, are however vital for viral 
replication in vivo. Nef ensures HIV infection by perturbing T-cell activation, 
increases virulence by down regulating CD4+ lymphocytes as well as stimulating 
the infectivity of the HIV virion.61–63 Vif prevents the antiviral host protein 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) 
from entering the HIV virion by targeting it for cellular degradation.64 HIV 
replication does not rely on Vif in most cells suggesting that these cells host a 
protein similar in function to Vif.52 Vpr is involved in the nuclear localization of the 
HIV preintegration complex (PIC) in non-dividing cells such as macrophages.65 
Vpu plays a role in CD4+ down regulation and increases the release of HIV 
virions from the infected cell surface.66,67 
 
Figure 1.2: Representation of the HIV-1 genome and some of the essential proteins that 
these genes express. Adapted and modified from www.stanford.edu, accessed 1/09/2013.
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1.1.4. The HIV lifecycle 
The human immune cells involved in HIV-1 infection and replication include 
macrophages, dendritic cells (DC) and T-lymphocytes where activated CD4+ 
lymphocytes are the major target for HIV infection.3,68 Upon HIV transmission, 
macrophages and DCs capture the cell free virus at the mucosal surface in vivo 
and present it to naive T-cells for infection and subsequent viral replication.68–72 
Since CD4+ T-lymphocytes are the major target for HIV infection, Figure 1.3 
briefly describes the HIV-1 life cycle in CD4+ lymphocytes. 
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Briefly, the HIV-1 life cycle , demonstrated in Figure 1.3, is carried out in multiple 
steps that begin when the gp120 of the virion binds to the CD4+ receptor on 
CD4+ lymphocytes as well as one of the co-receptors, CCR5 or CXCR4, 
consecutively.73,74 The binding of gp120 to the CD4+ receptors and co-receptors 
induces a conformational change that allows the gp41 to insert its hydrophobic 
terminus into the host cell membrane facilitating fusion of the host- and viral cell 
membranes (Step 2 in Figure 1.3). The HIV envelope subsequently propels the 
viral capsid into the cytoplasm of the host cell.75–77 Upon entering the host cell, 
the p24 capsid is digested, subsequently releasing the viral genetic material, viral 
replication enzymes and associated proteins into the cytoplasm of the host cell. 
The viral genetic material, two single RNA positive strands, is reverse transcribed 
to viral cDNA by error-prone RT (Step 3 in Figure 1.3).78 A tetramer of IN collates 
with Vpr, p6, p7 matrix, and host proteins such as BAF, Gemin2, HAT p300, 
HMGA1, HSP 60, Human EED protein, Importin 7, IN interactor 1, LEDGF/p75, 
and UNG2 thus forming the PIC.79–88 The PIC translocates into the nucleus of the 
host cell where IN catalyzes the irreversible integration of the pro-viral DNA into 
the host DNA forming the provirus (Step 4 in Figure 1.3). The viral transcription 
factors transcribe the integrated DNA and the resulting mRNA is exported to the 
cytoplasm (Step 5 in Figure 1.3). The mRNA is subsequently translated to 
polypeptide chains that are cleaved by viral or host proteases to synthesize viral 
proteins in the endoplasmic reticulum (ER).89 These viral proteins are transported 
to the surface of the cells and are embedded in the host cell membrane where 
these proteins collate with other viral proteins (Step 6 in Figure 1.3). The viral 
proteins cluster together with essential host proteins thereby forming an immature 
virion. The immature virion subsequently buds off from the cell surface and 
together with a portion of the host cell membrane forms the viral envelope. When 
the Gag polyprotein chains of the immature virion are fully cleaved by PR, it 
forms an infectious mature virion that has the ability to infect new host cells (Step 
7 in Figure 1.3).90  
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Figure 1.3: Schematic representation of the seven steps in the HIV-1 lifecycle: 1 - Binding and 
fusion of the gp120 on the surface of the HIV virion and the host CD4+ lymphocytes. 2 - Insertion of 
viral replication enzymes, RNA and accessory proteins into the host cell. 3 - Reverse transcription 
of viral RNA to DNA. 4 - Integration of pro-viral DNA into the host DNA in the nucleus. 5 - 
Transcription of pro-viral DNA to mRNA to synthesize viral proteins. 6 - Immature virions forms 
when viral proteins cluster together and buds off from the host cell membrane. 7 - Protease cleaves 
viral polyproteins into individual viral proteins and is known as mature virions. Illustration obtained 
and modified from www.niaid.nih.gov, accessed 12/07/2013.
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1.2. HIV treatment and drug discovery 
1.2.1. Current antiretroviral treatment  
Each stage of the viral life cycle represents a potential antiretroviral drug target. 
There are currently four drug classes in the HIV life cycle namely; viral entry 
inhibitors, RT inhibitors, IN inhibitors (INI) and PR inhibitors (PIs).92,93 Highly 
Active Antiretroviral Therapy (HAART) is a combination of antiretroviral drugs that 
comprise at least two different drug classes that delay disease progression from 
HIV to AIDS by effectively suppressing the viral load and increasing the genetic 
barrier to the development of antiretroviral drug resistance.94  
 
Antiretrovirals targeting RT encompass Nucleoside RT inhibitors (NRTI), 
nucleotide RT inhibitors (NtRTI) and non-nucleoside RT inhibitors (NNRTI). AZT 
was the first NRTI approved by the FDA in 1985 and functions as faulty DNA 
blocks that are incorporated into the newly synthesized viral DNA, resulting in 
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chain termination.95,96 NRTIs and NtRTIs share a similar mechanism of action in 
that they are analogues of the naturally occurring deoxynucleotides required for 
DNA synthesis.97 These NRTIs and NtRTIs analogues differ from the naturally 
occurring deoxynucleotides as the analogues do not possess a 3’-hydroxyl on the 
deoxyribose moiety required for the formation of a 5’-phosphodiester bond that 
facilitate DNA chain extension.97–99 NRTIs and NtRTIs compete and replace the 
naturally occurring deoxynucleotides thereby impeding viral DNA synthesis. 
NRTIs require activation before they are incorporated into viral DNA.99 These 
NRTIs are activated when cellular kinase enzymes phosphorylate the 
deoxyribose moiety on the NRTIs.97 Current NRTIs available are lamivudine, 
AZT, emtricitabine, abacavir sulphate, stavudine, didanosine, dideoxyinosine, 
emtricitabine (FTC) and enteric coated didanosine.100 NtRTIs evade the 
conversion step of nucleosides to nucleotides. Current NtRTIs available are 
tenofovir disoproxil fumarate (TDF) and adefovir.100 NNRTIs bind to a site on RT 
distant from the binding site subsequently inactivating the enzyme 
allosterically.99,101,102 Currently available NNRTIs are nevirapine, efavirenz, 
delavirdine, etravirine and rilpivirine.100,103 
The discovery of PIs was pivotal as it was the beginning of combinational 
therapy, HAART. PIs are substrate analogues of the HIV aspartyl protease 
enzyme that bind to the active site of protease subsequently blocking the activity 
of the enzyme and therefore preventing the cleavage of viral proteins. These 
uncleaved viral proteins are then considered defective and therefore the virion 
cannot mature into an infectious particle.104 FDA approved PIs include nelfinavir, 
saquinavir, darunavir, ritonavir, fosamprenavir calcium, indinavir and tipranavir.100 
Entry inhibitors such as maraviroc, a co-receptor antagonist, inhibit viral entry into 
the host cell by blocking CCR5 on the host cell. FDA approved fusion inhibitor, 
enfuvirtide, prevents the fusion of the viral envelope and cell membrane by 
interacting with gp41 thereby inhibiting viral replication.100,105,106  
The latest class of antiretrovirals to obtain FDA approval inhibit viral integration 
into the host genome by targeting IN.107 As such, IN is considered to be one of 
the most favourable antiretroviral targets in the replication cycle of HIV. 
Raltegravir (RAL), an IN strand transfer inhibitor (INSTI), was the first INI that 
was FDA approved in 2007.108,109 Elvitegravir (EVG) was FDA approved in 2012 
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and dolutegravir (DTG) is the most recent INSTI that was FDA approved in 
August, 2013.110 RAL is further discussed in section 1.2.3.2. 
A single tablet regimen, QUAD pill (Gilead Science, USA), was approved in 2012 
that encompasses a fixed dose-combination of EVG, TDF, FTC and cobicistat.111 
EVG, TDF and FTC confers HIV antiretroviral activity by suppressing viral 
replication whereas cobicistat inhibits the EVG metabolizing enzyme cytochrome 
P450 3A consequently increasing the concentration of EVG in blood.100,112,113 
Despite the successful development of antiretrovirals, obstacles such as the 
transmission of HIV-1 drug resistant viruses loom. Due to its high mutation rate, 
as well as antiretroviral drug pressure, the HIV-1 virus ultimately develops 
resistance to all currently available antiretrovirals.114,115 As such, individuals who 
harbour these resistant strains have less antiretroviral treatment options resulting 
in an increase in mortality.116 By using drug combinations such as those 
recommended in HAART, the dosage required for effective treatment decreases, 
the genetic barrier to developing drug resistance mutations increases, and 
therefore the emergence of drug resistant HIV-1 viral strains is delayed.117 
Resistant viral mutations against RAL are further discussed in section 1.2.2.5. 
1.2.2. Drug discovery and development 
Drug discovery is the process whereby new therapeutics against a specific target 
is discovered. Figure 1.4 describes the lengthy and costly process of drug 
discovery and its low drug output rate. It is estimated that the entire drug 
discovery and development process ranges between 10-15 years with an 
approximate cost of up to $1.5 billion per successful drug.118 It is estimated that 
only one drug candidate of a possible 5000 -10 000 tested will be FDA approved. 
Drug discovery and development stages include: drug discovery, preclinical trials, 
clinical trials, and FDA review and post-FDA approval.119 As demonstrated in 
Figure 1.4, the typical steps involved in early drug discovery include: target 
identification and validation, development of a compound screening assay 
followed by the identification of a HIT compound through random- or rational 
approaches that ultimately leads to lead optimization.117 A HIT compound is 
defined, in the context of this study, as a compound that confers inhibition against 
a specific target. 
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Figure 1.4: Representation of the stages involved in drug discovery and development 
depicting the approximate success rate of the compounds, the average cost contributed to 
each stage and the duration of each stage.  
1.2.2.1. Random screening approach 
Random screening involves the biological screening of compound libraries and 
does not require any prior knowledge of the compounds that are screened 
against a specific target. Compound libraries are typically compiled through 
combinatorial chemistry, parallel synthesis, drug repositioning and natural 
product libraries as recapitulated in Figure 1.5.120 Combinatorial chemistry 
involves the compilation of molecules related to a particular scaffold that is active 
against a specific target (biased library) or a collection of randomly synthesized 
compounds that are not limited to a single target (unbiased library).121 Parallel 
synthesis involves the synthesis of compounds in parallel using spatially 
separated compartments.122 Furthermore, drug repositioning is based on existing 
drugs that are redistributed in novel drug targets (further discussed in section 
1.2.2.4).123 The compounds screened in random biological assays are not 
restricted to synthesized molecules but also low-molecular-weight natural 
products derived from plants that comprise natural product libraries.124 The 
screening of these compound libraries are often screened through High 
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Throughput Screening (HTS) where biological screening assays are amended to 
an automated system.121 
Random screening has been documented in HIV research in Africa where 
screening of natural products was predominant.125–127 Through random 
screening, a plant widely used in South Africa as traditional medicine, 
Sutherlandia frutescens, has been reported as a possible treatment for HIV/AIDS 
by increasing CD4+ counts, stimulating appetite and decreasing viral loads.128 
This plant extract is in phase II clinical trials and the results thereof are expected 
in 2013.117 High running cost is often associated with HTS and since compounds 
are randomly screened without prior knowledge of its interaction with the target, 
this random approach results in a high failure rate.117 As such, random 
approaches in early drug discovery are not conducive to cost effectiveness. 
However, random screening is the preferred approach when searching for HITS 
with novel mechanisms of action since these compounds are not designed 
against a specific target.120 
1.2.2.2. Rational design approach 
The rational design drug discovery approach is based on selecting compounds in 
available compound libraries that are likely to have activity against the specific 
target.129 These compounds are selected due to prior investigation with their 
target of interest.129 Rational design can be classified as ligand-based design or 
structure-based design summarized in Figure 1.5. Structure based design 
approach is where the 3 dimensional (3D) structure of the specific target is 
exploited in order to develop suitable molecules that would interact with the 
target.130 The structure of the target can be determined biologically through X-ray 
crystallography or nuclear magnetic resonance (NMR) spectroscopy. The 
structure of the target may also be elucidated through computational methods 
such as threading and homology modelling.131 Homology modelling relies on the 
known 3D structure of a homologous target that serves as a template for the 
prediction of the 3D structure of the new target.131 When there is no known 
structure available of an homologous target, the 3D structure of the target of 
interest is predicted using its amino acid (aa) sequence by comparing it to a 
database comprising known folds.131,132 De novo drug design is based on the 
structure and aa orientation of the active site. Ligands are then designed specific 
to the active site of the target.133 
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Figure 1.5: A schematic summation of the random and rational approaches in early drug 
discovery that ultimately lead to HIT optimization. Herein, some of the tools involved in random 
screening and rational design are listed that ultimately lead to HITcompounds that enter preclinical 
trials.  
Ligand-based design involves screening of molecules that are similar or related 
to the pharmacophore associated with a specific target. Figure 1.5 briefly lists the 
approaches used in ligand-based drug design. Pharmacophore modelling and 3D 
quantitative structural activity relationships (QSAR) are the most common ligand-
based design tools.134 Both structure- and ligand-based drug designs are typically 
linked with virtual screening (VS) that aid in HIT identification.135 VS has become 
an integral part of drug discovery as it predicts the interaction of ligands with a 
specific target through computational methods. Rational drug design is 
advantageous when linked to computational methods since it evaluates the 
interaction of compounds with a specific target through rapid and low cost 
simulation. An example of successful rational drug design include the discovery 
of PIs such as ritonavir and indinavir.136  
Furthermore, rational drug design can be extended to predictive ADMET 
(absorption, distribution, metabolism, excretion and toxicity) studies to describe 
the pharmacological properties of compounds before they enter preclinical 
trials.137 All ADMET descriptors of drugs can be tested in silico.137 The absorption 
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properties of drugs refer to the ability of compounds to enter the bloodstream via 
human intestinal absorption (HIA) after oral administration which is dependent on 
the solubility and permeability of the drugs.138,139 Chris Lipinski140 pioneered the 
Lipinski rule of 5 (Ro5) paradigm that identify the parameters that contribute to 
poor oral bioavailability of synthetic compounds. The Lipinski rule of 5 states that 
drug properties should adhere to the following rules for it to be considered as 
drug like: the molecular weight (MW) of the compound should be less than 500 
Daltons (Da); the water partition coefficient (cLogP) should be less than 5; there 
should be less than 5 hydrogen bonds donors; there should be less than 10 
hydrogen bond acceptors.140 The distribution of a compound determines ability of 
a compound to reach its specific target in the body such as the organs, muscles 
and crossing the blood brain barrier (BBB).141 In addition, the distribution of 
compounds includes the ability of the compound to bind to plasma binding 
proteins in blood consequently delivering drugs to its specific target.142 After oral 
bioavailability, most drugs are metabolized in the liver by CYP p450.143 Important 
metabolic drug properties include metabolic stability, drug-drug interactions and 
toxicity influenced by the metabolism of a drug.141,144 Drugs are then removed 
from the body through kidney excretion, biliary excretion or fecal excretion. Dose 
dependent studies of drugs are conducted to determine whether these drugs are 
toxic to cells in the body.142  
1.2.2.3. High Throughput Screening and automation  
HTS is a high-tech approach in drug discovery that has gained popularity in the 
last two decades due to its ability to screen large compound libraries against 
specific targets.121 As mentioned in section 1.2.2.1, HTS is a technique widely 
used in random drug screening. HTS used on an automated platform aims to 
reduce reagent use, human error and extensive methodology thus accelerating 
drug development.145 HTS laboratories have the ability to screen up to 10 000 
compounds per day whereas ultra HTS (uHTS) laboratories are more advanced 
in their screening capabilities and ≥100 000 compounds can be screened per 
day.146 In order to reduce cost, automation together with miniaturization has 
become popular. Miniaturization decreases the volume of the biological- and 
chemical reagents by using half-area well plates or plates with higher well 
densities. 147  
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Automation has rapidly become the driving force of HTS in drug discovery and 
can be classified into three types: hand-held automation, unit automation and 
integral automation.148 Hand-held automation includes devices that are held and 
controlled by a human operator. Such automation is widely used in laboratories in 
low throughput screening.149 Unit automation is the most common type of 
automation that includes automated benchtop systems that do not require 
constant control by a laboratory operator. Unit automated devices are generally 
integrated into fully automated workstations termed integral automation devices. 
These workstations comprise automated liquid handling systems on an X, Y and 
Z axis that have the ability to aspirate and dispense liquid. In addition, these 
workstations contain a robotic arm that has the ability to transfer microplates and 
test tubes to integrated unit automated devices. Fully integral automated 
workstations are programmed with software that controls and schedules 
experiments as well as identify errors made during the experiment. These fully 
integral automated workstations can ease complex HTS screening by amending 
biological screening assays to an automated robotic platform. Biological screen 
assays are optimized and amended to an automated system ensuring stable 
assay signal and sensitivity.120,150 Fully automated systems are advantageous as 
these systems provides higher data quality, rapid screening of small molecules 
and they are less laborious than manual assays.121,151 
 
1.2.2.4. Drug repositioning 
Drug repositioning is a method in drug discovery which involves the redistribution 
of FDA approved drugs or drugs that have been in clinical trials, into new disease 
models.123 Drug repositioning is advantageous in drug development since the risk 
profile and adverse effects of the drugs are already known thereby reducing cost 
as well as development time by 3-5 years.152 The average cost of a successful 
repositioned drug is estimated at $8.4 million compared to $1.5 billion when 
developing a new drug.153 Compound libraries comprising of repositioned drugs 
include the National Institutes of Health (NIH) Clinical Collection (NCC), the John 
Hopkins clinical compound library and the Developmental Therapeutics 
Programme (DTP) approved oncology drug set.154  
 
 Introduction 
15 
 
1.2.2.4.1. The NIH Clinical Collection compound library 
The NIH have implemented drug repositioning by assembling a compound library 
comprised of the NCC I and NCC II that contain 446 and 281 small molecules, 
respectively. The NCC forms part of the NIH roadmap Molecular Libraries 
Screening Centers Network (MLSCN) in a mission to expand the bioactivity data 
on these compounds and to re-supply compounds that are FDA approved or that 
have undergone clinical trials. The compounds in the NCC are selected based on 
their purity, solubility properties and commercial availability. The molecules in the 
NCC have been classified according to their therapeutic categories and are 
depicted in Figure 1.6. Since most of these molecules have been in clinical trials 
phase I to III, they have well characterized safety profiles and high drug-like 
properties, hence easing drug development. These molecules can be used as a 
basis for medicinal chemistry optimization and might possibly be useful for new 
drug targets such as HIV-1 IN.154 The success of drug repositioning using the 
NCC has been reported in several studies.155-158 Corcoran and co-workers155 
have identified a novel mechanism of action of histone deacetylase inhibitors in 
protein aggresome models. Stavrovskaya and co-workers156 tested the NCC 
small molecules as mitochondrial permeability transition inhibitors and identified 
28 small molecules that delayed mitochondrial permeability. Lunn and co-
workers157 conducted a HTS study to identify a compound that increase the 
production of survival motor-neuron 2 (SMN2) luciferase reporter protein in 
patients with paediatric neurodegenerative disease spinal muscular atrophy 
where Ibuprofen was found to selectively increase the production of SMN2 
luciferase reporter protein. Rothstein and co-workers158 randomly screened 1040 
FDA approved drugs that included the small molecules from the NCC compound 
library to identify stimulators of the dominant astroglial protein, glutamate 
transporter (GLT1) that inactivates glutamate which is a neurotransmitter in the 
nervous system. They discovered that beta (β)-lactam antibiotics found in the 
NCC stimulated GLT1 expression which consequently conferred neuroprotection.  
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Figure 1.6: The NIH Clinical Collection (NCC) small molecule therapeutic indication. Drugs 
used in central nervous system (CNS) therapy (136) are predominant in the NCC while molecules 
used in renal, reproductive control, anti-lipemic, hematolic and dermatological therapy are minimal 
(< 10). Diagram extracted from www.nihclinicalcollection.com, accessed 20/10/2013.
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1.2.3. HIV-1 integrase as a drug target 
1.2.3.1. The structure of HIV-1 integrase and its function 
The HIV-1 IN enzyme is one of three enzymes essential for HIV replication that 
belongs to the transposase family of DNA transferases. Its function is to catalyse 
the integration of newly synthesized viral DNA into the host chromosomal 
DNA.107,159 The 32 kilodalton (kDa) protein, depicted in Figure 1.7, is encoded 
from the 3'-terminus of the pol gene and is comprised of 288 aa sectioned into 
three functional domains: the N-terminal domain (NTD), the catalytic core domain 
(CCD) and the C-terminal domain (CTD).160–162 The NTD (aa 1-50) consists of a 
dimeric helix-turn-helix that has a conserved histidine (His) and cysteine (Cis) 
motif (HHCC) coordinated by zinc.163 The CCD (aa 51-212) is comprised of six β-
strands surrounded by six α-helices and contains the D64D116E152 (DDE) motif 
consisting of Asp64, Asp116 and Glu152 acidic residues essential to the catalytic 
activity of IN. The divalent metal cation Mg2+, coordinates Glu152, Asp64 and 
Asp116 making it a fundamental cofactor in the catalytic domain.107 These aa 
residues are conserved throughout the IN CCD domain of retroviruses.164–166 The 
CTD (aa 213-288) is less conserved and has a SH3-like fold that facilitates non-
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specific DNA binding.163 Overall, all three domains of IN are involved in DNA 
binding and multimerization that is important for integration.160 
 
 
Figure 1.7: The schematic representation of the HIV-1 structural domains: the zinc 
coordinated N-terminal domain, the Mg
2+
 coordinated catalytic core domain and the non-specific 
DNA binding C-terminal domain. Illustration obtained and modified from McCol and Chen, 2010.
167
 
When zinc binds to the HHCC motif in the NTD, it promotes multimerization 
resulting in the formation of tetramers which is the functional state of IN.168 Each 
tetramer consists of a dimer of dimers that is linked by the six α-helices of the 
CCD subsequently forming a flexible loop between the helices of each monomer 
that plays a vital role in the integration of DNA (Figure 1.8).107 The positive 
charge residues in the area spanning from the end of the CCD on one monomer 
to the CTD of the other monomer plays a crucial role in viral DNA stabilization for 
subsequent integration.  
  
Figure 1.8: The structure of the HIV-1 integrase (IN) dimer. The IN dimer comprise the C-
terminal domain and the catalytic core domain. Each monomer is denoted in a different colour. 
Structure obtained from mapdev.rutgers.edu, accessed 29/10/2013. 
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IN catalyses irreversible viral integration in a two-step transesterification reaction: 
3’-end processing and the ST reaction. Figure 1.9 briefly describes the integration 
of viral cDNA into host DNA. Firstly, the IN cleaves conserved dinucleotides, CA, 
at the linear 3’-viral DNA end in the cytoplasm resulting in CA overhangs 
subsequently exposing the hydroxyl groups (Step 1 in Figure 1.9). IN together 
with the processed viral DNA and other viral and host proteins forms a PIC and is 
transported into the nucleus where the ST reaction occurs (Step 2 in Figure 1.9). 
In the presence of Mg2+, the exposed hydroxyl groups of the processed viral DNA 
attack the phosphodiester bonds on the host DNA at the site of insertion. 
Integration is completed when the two unpaired nucleotides at the 5’-end of the 
viral DNA are removed, the gaps between the host- and viral DNA are filled and 
the strands are covalently ligated by the host DNA repair proteins.164,170–172 The 
host cell genome now contains the viral genetic material necessary to create 
progeny viruses.   
 
Figure 1.9: Schematic representation of HIV-1 integration catalyzed by integrase (IN). In the 
first step of integration, known as 3’-end processing, IN binds to the viral DNA subsequently 
cleaving the CA dinucleotides at the 3’-end thereby exposing hydroxyl groups. Secondly, the 
hydroxyl groups of the processed viral DNA attacks the host DNA resulting in integration. The DNA 
is ligated using host DNA repair proteins thereby forming a provirus. Adapted and modified from 
Suzuki and co-workers, 2012.
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1.2.3.2. The mode of action of the integrase strand transfer inhibitor, 
raltegravir 
RAL is derived from a class of inhibitors that contain a distinct β diketo acid 
(DKA), 4-Aryl-2,4-diketobutanoic acid, moiety that demonstrate ST inhibition. The 
most potent β-DKA compound, L-731,988, exhibited a half maximal inhibitory 
concentration (IC50) of 80 nanomolar (nM).
174 By substituting chemical moieties of 
DKAs, Merck Research Laboratories discovered that dihydroxypyrimidine 
carboxamide was an effective ST inhibitor selective for HIV IN only. RAL, a 
pyrimidine carboxamide, was the most potent derivative of the 
dihydroxypyrimidine carboxamides identified and demonstrated nanomolar 
activity with an IC50 = 7nM.
175 RAL inhibits the ST reaction by chelating the 
divalent metal cations in the active site that modulate IN activity.176 The binding of 
the RAL to the CCD of IN is depicted in Figure 1.10. The chemical structure of 
RAL possess a 5-hydroxy-3-methylpyrimidin-4(3H)-one (HMPO) chelator group 
that combines with an amide carbonyl oxygen atom providing the essential 
coplanar oxygen atoms that binds to the Mg2+ in the DDE motif of the 
CCD.108,177,178 
 
EVG and DTG are DKA derivatives with similar structural moieties as RAL and 
thus these derivatives exert ST inhibition in a similar mechanism of action as 
RAL. 110,179 RAL and EVG in the HAART regimen are currently at the forefront of 
HIV therapy that vastly reduces viral replication in HIV treatment-naïve patients 
as well as HIV treatment experienced patients. RAL and EVG are novel class 
inhibitors and are therefore active against viral strains resistant to NRTIs, 
NNRTIs, PIs and entry inhibitors.180  
                                       
Figure 1.10: The binding of raltegravir (RAL) to the active site of integrase (IN). Coplanar 
oxygen groups of RAL bind to the Mg
2+
 coordinated catalytic core domain of the HIV-1 IN binding 
site. Diagram extracted from Agrawal and co-workers.
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1.2.3.3. Resistance mutations against raltegravir and other integrase 
inhibitors 
The emergence of viral resistant mutations compromise the efficacy of the 
antiretroviral agents.182 Viral resistant mutations in relevant HIV-1 genes may 
confer cross-resistance to antiretroviral agents within a drug class and can 
therefore limit treatment options for treatment experienced patients.182 To 
overcome the drug failure concern, novel drug classes or second generation 
antiretrovirals within a drug class should be developed.182 Mutations in the viral 
genome, caused by the error-prone RT as well as drug pressure, attribute to viral 
resistance against antiretroviral agents. O’Neil183 described the frequency of 
mutations due to RT as 0.85bp/genome/replication cycle. Multiple viral mutations 
emerge with increase in replication cycles resulting in a quasispecies of viruses 
that may hinder viral replication or confer resistance against antiretrovirals.182 The 
extent of resistance can be quantified by analysing the properties of the virus 
such as the degree of resistance through fold-change IC50 (FCIC50) and the 
replication capacity (RC) of the antiretroviral drug resistant virus relative to wild 
type wild type.182 
Recent reports have indicated that virological failure due to RAL treatment is 
attributed to resistance mutations in the IN catalytic domain.184,185 Resistance 
against RAL is conferred in a stepwise process through mutations in one of three 
distinct pathways INN155H, INQ148H/R/K or INY143R/C/H.
186,187 INQ148H is the predominant 
pathway in viral resistance against RAL followed by INN155H and INY143R/C/H.
188 The 
mutations observed emerge consecutively where studies conducted by Malet and 
co-workers189 demonstrated that INN155H is most likely the initial mutation that 
shifts to the INQ148H mutation. The INQ148 pathway mutations have demonstrated 
stronger RAL resistance than INN155H pathway mutations.
189 However, these 
primary mutations are often associated with impaired IN that subsequently 
reduce the RC of the virus. To deter this, primary mutations are usually coupled 
with secondary mutations that restore RC as well as confer strong resistance 
against RAL. INQ148 is usually associated with ING140S and INN155H is associated 
with INE92Q.
190 Delelis and co-workers190 elucidated that INQ148H as a single 
mutation confers RAL resistance but impairs RC. ING140S as a single mutation 
does not confer resistance but restore RC when coupled to INQ148H. Therefore, 
INQ148H in combination with ING140S produces a virus that has a high RC and is 
greatly resistant to RAL.190 Likewise, INN155H in combination with INE92Q or INT97A 
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increase both RC as well as resistance against RAL.190 The primary mutation, 
INY143C/R, reduces RAL susceptibility 5-20 fold however when coupled with INT97A, 
RAL susceptibility decreases by >100 fold.191–193 Resistant mutations against 
RAL were also observed in patients failing EVG therapy indicating cross 
resistance mutations between RAL and EVG.194,195 Furthermore, DTG conferred 
the mutations, INE92Q and INQ148H/R, only in RAL-experienced patients.
196 INT124A 
was observed in treatment-naive patients and conferred low-level resistance 
against DTG.196 In addition the primary mutation INR263K was observed in 
treatment-naive patients where viral replication decreased by 20% and a low-
level of DTG resistance was observed (2-6 fold).197 Secondary mutations INH51Y, 
INE138K or INM50I were observed that increased DTG resistance but decreased 
viral replication.198 
1.2.3.4. In vitro assays used to identify HIV integrase inhibitors 
Several assays have been developed to measure IN activity and identify 
inhibitors. Such assays include gel based assays; fluorescent resonance energy 
transfer (FRET)-based assays, microarray screening (mARSC) and in vitro 
microtiter plate assays that have been developed to recreate the integration 
process by using recombinantly expressed IN and double stranded (ds) DNA 
resembling viral DNA ends.199–201 Most HIV-1 IN assays follow similar principles 
where viral dsDNA is immobilized onto a solid phase-support thereby 
quantitatively measuring IN activity by monitoring the fusion of the viral dsDNA 
with a labelled target DNA (tDNA).145 These assays are used to screen HIV-1 IN 
activity in isolation and in the presence of possible inhibitors where ST and 3’-end 
processing can be measured consequently identifying or characterizing 
inhibitors.202,203  
1.2.3.5. HIV integrase assays amenable to automation 
Biochemical assays amended to HTS are desirable as it expedites the screening 
of small molecules and identification of INI. Such assays are responsible for the 
identification of several INI.204,205 For an assay to be suitable for automation it 
should possess the following qualities: homogenous assay, sensitive detection 
method, preferably conducted in microplates, rapid and minimal steps and 
incubation times.145 HIV-1 IN assays amenable to an automated system include 
time resolved FRET (TR-FRET), amplified luminescent proximity homogenous 
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assay (Alpha)-LISA, scintillation proximity assay (SPA) and more recently the 
cellular IN screening (CIS) assay.202,206,207  
1.2.3.6. Automation of an HIV integrase scintillation proximity assay 
(SPA) 
Although several assay formats can be adapted to automated systems, the SPA 
is the method that is highly compatible with automation since it is a homogenous 
biochemical assay used for biological screening of a large scope of biochemical 
processes in a rapid and sensitive approach. Since the bound and free 
radiolabeled molecules can be detected, the assay does not require any 
centrifugation, physical separation and filtration steps therefore easing robotic 
complexity when used in automation.208 The SPA is advantageous in automation 
with its high detection sensitivity, simplicity and fewer separating steps that 
reduce cost, time and potential errors.208 The principle of the assay is based on a 
radiolabeled molecule when in close proximity to the SPA bead, activates a 
scintillant that emits light thereby monitoring the activity of a biomolecule.208 The 
main components of the SPA are the radioactive isotopes and supportive 
material such as scintillation beads or scintillation microplates. The most common 
SPA beads are polyvinyltoluene (PVT) beads because they contain high 
efficiency scintillants within its matrix that are excited when in close proximity with 
a radioactive isotope. The PVT bead is coated in hydrophilic polyhydroxy film that 
masks hydrophobicity thus reducing non-specific binding.145 The coated film 
covalently couples generic capture molecules such as avidin, streptavidin, 
glutathione as well as polyclonal secondary antibodies. The SPA has been 
adapted to radioactive isotopes such as tritium (3H), 22P, 14C, 35S and 125I. 
However, 3H is the preferred radioisotope as the β-particles, released upon 
decay, has a short pathlength of 1.5 micrometer (µm) in aqueous solution that 
satisfies the energy transference distance criteria for SPA.145  
The principle of this HIV IN SPA, illustrated in Figure 1.11, is based on the 
binding of the 3H host/tDNA (3H-tDNA) to the IN-viral/donor DNA (dDNA) complex 
via a ST reaction bringing the 3H-tDNA in close proximity with the scintillant in the 
SPA beads. The β-particles emitted, when 3H decays, transfer energy to the 
scintillant resulting in light emission. If the ST reaction is inhibited by an inhibitory 
compound, the 3H-tDNA will not be captured by the IN-dDNA complex that is 
bound to the scintillation bead. The energy emitted by the 3H-tDNA will then 
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dissipate into the aqueous solution thus no light emission will occur. The intensity 
of radiation emitted is quantified through scintillation counting. The SPA in HIV-1 
IN studies have been reported where Hu and co-workers206 screened a large 
compound library of 1 million compounds using a SPA to identify possible IN 
inhibitors.  
 
Figure 1.11: The principle of the HIV-1 integrase (IN) scintillation proximity assay (SPA). The 
assay is based on radiolabeled host target DNA (
3
H-tDNA) that releases β-particles upon 
radioactive decay. When strand transfer (ST) occurs, the 
3
H-tDNA is in close proximity with the viral 
DNA attached to the SPA bead. The β-particles released activate the scintillant in the SPA bead 
consequently emitting light. When ST is inhibited, the 
3
H-tDNA is not in close proximity with the 
scintillant and thus its β-particles dissipate in the aqueous solution. Illustration extracted and 
modified from www.perkinelmer.com, accessed 31/07/2013.
209
 
1.2.4. Hypothesis 
There is no published data on screening the NIH Clinical Collection I and II for 
potential HIV-1 IN inhibitors. We hypothesize that screening of the NIH Clinical 
Collection I and II using an automated HIV-1 IN SPA may identify a possible IN 
ST inhibitor. 
1.2.5. Study aims and objectives 
The overall aim of this study is to adapt an HIV-1 IN assay onto an automated 
platform in order to screen a well-defined compound library for potential HIV-1 IN 
inhibitors. This will be achieved by completing the following objectives: 
1. Expression and purification of recombinant HIV-1 IN proteins (subtype B). 
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2. Optimization and validation of the HIV-1 IN inhibition SPA  
3. Adaption of the optimized HIV-1 IN inhibition SPA to an automated format 
4. Biological evaluation of the NCC using the automated HIV-1 IN inhibition 
SPA. 
5. Further development should HIT compounds be identified; including 
validation in secondary assays, mutation profiles, cell-based assays, 
ADMET evaluation and molecular docking. 
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2.1. Recombinant wild type HIV-1 subtype B integrase 
expression and purification 
The HIV-1 IN expression and purification protocol was extracted from Marchand 
and co-workers210, Bushman and co-workers211 and Fish212 to which several 
parameters have been modified.  
2.1.1. HIV-1 Pol gene induction 
Luria Bertani (LB, Laboratorios Conda, Spain) supplemented with 100 microgram 
per millilitre (µg/ml) ampicillin (AMP, Melford, UK) and 100µg/ml chloramphenicol 
(Dulfecha Biochemie, Spain) was inoculated with transformed Eschericia (E) coli 
BL 21 pINSD.His (NIH AIDS Research and Reference Reagents Programme; 
Catalogue number (Cat #) 2957) and incubated overnight shaking at 37°C. The 
overnight culture was diluted 100 fold in 350ml LB supplemented with 100µg/ml 
AMP and 100µg/ml chloramphenicol. The culture was grown in a shaking 
incubator at 37°C and the optical density (OD) thereof was intermittently read at 
600nm using the Spectramax Plus384 spectrophometer (Molecular Devices, 
USA) until an OD of 0.6 was reached. This OD was indicative of the logarithmic 
phase of the bacterial cell growth. The culture was then induced with 1 millimolar 
(mM) isopropyl β-D-1-thiogalactopyranoside (IPTG, Thermo Fisher Scientific, 
USA) and incubated for an additional three hours. The pellets of the induced cell 
lysate were collected after centrifugation at 3220 x g for 30 minutes at 4°C. 
2.1.2. Bacterial cell lysis 
The pellets collected after centrifugation of the induced cell lysate were 
resuspended in Lysis Buffer (10mM MgCl2, 0.25% 3-[(3-Cholamidopropyl)-
dimethylammonio]-1-propanesulfonate (CHAPS, Sigma Aldrich, USA), 1mM 
phenylmethanesulfonylfluoride (PMSF, Thermo Fisher Scientific, USA) and 200 
micrograms per microlitre (µg/µl) DNAse (Sigma Aldrich, USA)  made up in 
Binding Buffer, pH 7.2 (1M NaCl, 5mM imidazole, 20mM HEPES, 5% glycerol, 
2mM β- Mercapthoethanol (B-Me, Sigma Aldrich, USA). The cell suspension was 
homogenised until the solution was uniform and stirred at 4 °C for 30 minutes. 
The homogenous cell solution was sonicated for 1 minute at 75Hz and 0.6 cycles 
using the Labsonic M ultrasonic processor (Sartorius, Germany). The lysate was 
then centrifuged at 15 000 x g at 4°C for 30 minutes from which the supernatant 
was collected. 
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2.1.3. Nickel-Affinity column chromatography 
The Protino Nickel (Ni) NTA Affinity column (Macherey Nagel, Germany) used to 
purify the His-tagged recombinant HIV-1 IN was prepared on the ÄKTA 
PrimePlus (GE Healthcare, UK). The column was equilibrated with five column 
washes of Binding Buffer, described in section 2.1.2, at a flow rate of 3ml/minute. 
The supernatant containing protein was loaded onto the Ni-column through the 
super-loop at a flow rate of 1ml/minute and the flow through was subsequently 
collected. The column was washed with 20 column washes of Wash Buffer 1, pH 
7.2 (1M NaCl, 20mM HEPES, 60mM imidazole, 10% glycerol, 2mM B-Me) at a 
flow rate of 3ml/minute followed by 20 column washes of Wash Buffer 2, pH 7.2 
(1M NaCl, 20mM HEPES, 150mM imidazole, 10% glycerol, 2mM B-Me). The 
protein was eluted at a gradient with Wash Buffer 2 as the starting buffer and a 
set final target of 100% Elution Buffer, pH 7.2 (1M NaCl, 20mM HEPES, 600mM 
imidazole, 10% glycerol, 2mM B-Me). The elution fractions were collected at a 
flow rate of 1ml/minute and 3ml per fraction. The eluate containing the protein 
was pooled and concentrated under liquid nitrogen using an ultra-filtration 
vacuum system (Merck Millipore, USA) with a 10 000 Da filter membrane. 
2.1.4. PD-10 Sephadex column 
The concentrated protein sample in Elution Buffer was buffer exchanged into 
Storage Buffer, pH 7.2 (20mM HEPES, 1M NaCl, 4mM EDTA, 2mM dithiothreitol 
(DTT, Thermo Fisher Scientific, USA), and 50% glycerol) by desalting the protein 
using a PD-10 Sephadex column (GE Healthcare, UK). The concentration of the 
purified recombinant IN protein was quantified using the NanoDrop installation 
version 1.3.1 software on the NanoDrop 2000 spectrophotometer (Thermo Fisher 
Scientific, USA) and calculated according to its molar extinction coefficient of 50 
460 using the equation: A=ε.c.l.   
2.1.5. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis  
Lysate samples were collected during the recombinant expression and 
purification of IN protocol, and analysed through Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis (SDS-PAGE). The positive control was a 
recombinant HIV-1 IN protein received from the NIH AIDS Research and 
Reference Reagents Programme (Cat #9420).213,214 Samples were diluted 1:1 
with Sample Loading Buffer (1M Tris-HCL pH 6.8, 10% glycerol, 10% SDS, 
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0.05% bromophenol blue, 5% B-Me) and boiled for two minutes. Samples were 
loaded onto a Mini Protean TGX 10% SDS-PAGE precast gel (Bio-Rad, USA) at 
a volume of 10µl alongside a Protein Molecular Weight (Mr) Marker (Bio-Rad, 
USA). The gels were equilibrated using a 1x Tris-Glycine-SDS (TGS) buffer 
(25mM Tris, 150mM glycine, and 0.1% SDS) and separated at 120 volts. After 
completion of the run, the gel was stained with Coomassie (0.025% Coomassie 
Brilliant Blue, 40% methanol and 7% acetic acid) using a staining protocol 
extracted from Sasse and Gallagher.215 Following an overnight shaking 
incubation at room temperature with Coomassie, the gel was destained with 
Destaining Solution I (40% methanol and 7% acetic acid in dH2O) for 
approximately two hours followed by an additional destaining with Destaining 
Solution II (4% methanol and 7% acetic acid in dH2O) for 3-4 hours. Gel images 
were captured using the gel capture software version 5.8 on the MiniBIS Pro Gel 
Imager (DNR Bio-Imaging Systems, Israel). The purity of the recombinant IN was 
determined using the GelQuant 1D gel analysis software version 4.1 (Bio-
Imaging Systems, Israel).  
2.1.6. Western blot analysis of the recombinant HIV-1 integrase 
To verify the expression of the HIV-1 IN protein, a Western blot was conducted 
using protocols extracted and modified from Bronstein and co-workers216 and 
Gallagher and co-workers.217 SDS-PAGE gels were incubated in Towbin Buffer 
(20% methanol in TGS Buffer) for 15 minutes at room temperature before 
transferring to a polyvinylidene difluoride (PVDF) membrane using the iBlot gel 
transfer stacks (Life Technologies, USA) according to the IBlot Transfer System 
instructions, (iBlot Transfer System, Life Science Technologies, USA). The PVDF 
membrane was probed with 1:1000 diluted anti-His.H8 (Abcam, UK) primary 
antibodies and 1:10 000 diluted rabbit anti-mouse horseradish peroxidase (HRP) 
linked IgG secondary antibody using the automatic Western blot system 
(Benchpro 4100, Life Technologies, USA). Briefly, the membrane was blocked 
with Blocking Buffer (5% Bovine Serum Albumin (BSA) in 1x TBST (420mM Tris 
pH 7.6, 137mM NaCl, 0.1% Tween 20)) and washed with 1x TBST before and 
after probing the membrane with primary- and secondary antibody. The 
recombinant IN protein was detected using Supersignal West Pico 
Chemiluminescent substrate (1:1 Luminol and peroxidase, Thermo Fisher 
Scientific, USA) and exposed to X-Ray film for 30 seconds. To further verify the 
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presence of recombinant HIV-1 IN, the membrane probed with anti-His.H8 was 
stripped and re-probed with 1:2000 diluted HIV-1 HXB2 IN antiserum (NIH AIDS 
Research and Reagents Programme; Cat #757)218 that targets aa 22-34 on the 
IN protein and 1:10 000 goat anti-rabbit secondary antibody. The membrane was 
stripped by washing it with 1x TBST thereafter incubated for 15 minutes in 
Restore Western Blot Stripping Buffer (Thermo Fisher Scientific, USA) and 
washed 3x for 5 minutes with 1x TBST. This was followed by an overnight 
incubation at 4ºC with Blocking Buffer. The stripped membrane was re-probed 
according to the method described above. 
2.2. Radiolabeling 3’-target DNA with 3H-dNTPs 
2.2.1. Lyophilizing 3H-dNTPs  
3H-radionucleotides, deoxycytidine 5’- [5-3H] triphosphate (dCTP) and 
deoxythymidine 5’-[methyl-3H] triphosphate (dTTP) (American Radiolabeled 
Chemicals, USA), were lyophilized using the DNA 120 Savant Speed Vac 
Concentrator (Thermo Fisher Scientific, USA) for approximately 90 minutes until 
no liquid residue was visible. The lyophilized radionucleotides were reconstituted 
in 35µl dH2O. The concentration of the 
3H radionucleotides was quantified using 
the Nanodrop 2000 and calculated using the Beer-Lambert law: A = εCl 
according to the molar extinction coefficients of 3H-dCTP and 3H-dTTP -  9.300 
and 9.600, respectively.  
2.2.2. Klenow fragment 3’-target DNA labelling with 3H-dTTP and 3H-
dCTP 
The complimentary target oligonucleotides to be radiolabeled, T 56-S 
(AAAAGGAGGAGAAGGAAAGGAGAGAGAGCGAATTAGCCCTTGGTC) and T 
56-A (AAAAGGAGGAGAAGGAAAGGAGAGAGAGGACCAAGGGCTAATTCG) 
(Inqaba Biotech, South Africa) were mixed in a 1:1 ratio at a final concentration of 
50 micromolar (µM) and annealed using the Eppendorf Mastercycler gradient 
PCR (Eppendorf, USA). The oligonucleotides were annealed under the following 
conditions: the reaction was heated at 95°C for two minutes then rapidly cooled 
to 68°C and held at 68°C for ten minutes. The reaction was then cooled down to 
storage temperature of 4°C over a 90 minute period. The 3’-end of the annealed 
linear tDNA was radiolabeled by inserting deoxynucleotides (dNTPs) at the 5’-
overhangs using the Fermentas Klenow fragment DNA labelling kit (Thermo 
 Materials and Methods 
 
29 
 
Fisher Scientific, USA). The reaction mixture consisted of 5µM linear tDNA, 150 
microcurie per millilitre (µCi/ml) 3H-dCTP, 150µCi/ml 3H-dTTP, 625µM mixed 
dNTPs, 1x kit Reaction Buffer, 10 units (U) Klenow fragment enzyme and was 
made up to a final volume of 20 microlitre (µl) with nuclease free water. The 
reaction mixture was incubated for four hours at 37°C and stopped by heating it 
at 75°C for ten minutes.  
2.2.3. Purifying the radiolabeled target DNA 
The QIAquick nucleotide removal kit (Qiagen, Germany) was used to purify 
unincorporated nucleotides from the 3H-tDNA. The high-salt concentration 
premixed kit Binding Buffer PNI was added to the 3H-tDNA mixture at a 10:1 ratio 
which was applied to a QIAquick spin column and centrifuged at 3800 x g for one 
minute. The flow through was discarded and the spin column was washed twice 
by adding 500µl premixed Buffer PE to the column and centrifuging it for one 
minute at 3800 x g. The spin column containing the 3H-tDNA was centrifuged for 
an additional one minute at 17 900 x g to remove residual ethanol from the 
premixed kit Buffer PE. The 3H-tDNA was eluted by adding 100µl dH2O to the 
center of the spin column membrane which was left to stand for one minute then 
centrifuged for one minute at 17 900 x g. The purified 3H-tDNA concentration was 
quantified using the NanoDrop 2000 and calculated using the MW of the tDNA 
(MW = 14136 grams per mole (g/Mol)).  
2.3. Scintillation proximity assay (SPA) 
The fundamental protocol for the SPA was derived from Grobler and co-
workers203 to which several parameters have been modified. All SPA experiments 
had the following controls: negative control (no IN), positive control (no 
test/inhibitory compound present) and 10µM RAL (Selleck Chemicals, USA). All 
test compounds were diluted in dimethyl sulfoxide (DMSO, Sigma Aldrich, USA). 
2.3.1. SPA optimization 
The SPA parameters that were modified include reaction buffers, divalent-metal 
ion cofactors (MgCl2 or MnCl2) and stop solutions. The reaction buffers were 
extracted from previously documented protocols described in Chow and co-
workers199 (20mM HEPES pH 7.5, 30mM NaCl, 10mM DTT and 0.5% IGEPAL 
(Nonidet-P40, Sigma Aldrich, USA), Dicker and co-workers219 (13.3mM DTT, 
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32mM MOPS pH 7.0, 0.067% IGEPAL (Nonidet-P40) and 12.8% DMSO), 
Grobler and co-workers203 (25mM HEPES pH 7.8, 50mM NaCl, 100µg/ml BSA 
and 5mM B-Me), and the Chow et al. buffer with 100µg/ml BSA. These buffers 
were further referred to as Buffer 1, Buffer 2, Buffer 3 and Buffer 4, respectively. 
The stop solutions and its constituents were extracted from Grobler and co-
workers203 and US patent no. 60/422,513.220 The stop solutions tested were 
62mM EDTA, 62mM EDTA with 63mM NaOH and 62mM EDTA with 63mM 
NaOH and 2.5M CsCl further refered to as stop solution 1,2 and 3, 
respectively.The optimized assay was validated by conducting dose-response 
experiments using RAL, EVG (Selleck Chemicals, USA) and 118-D24 (NIH AIDS 
Research and References Reagents Programme; Cat # 9957).221,222 
2.3.2. Preparation of the streptavidin coated SPA bead complex 
A 10x Reaction Buffer was prepared containing 200mM HEPES (pH 7.5), 300mM 
NaCl, 50mM DTT and 0.5% IGEPAL (Nonidet-P40). PVT streptavidin coated 
scintillation beads (GE Healthcare, UK) were reconstituted in 1x Reaction Buffer 
at a final concentration of 10mg/ml. Pre-processed biotinylated dDNA (U5 top 
strand, Biotin 5’-ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3’ and U5 
complimentary bottom strand 5’-ACTCCTAGAGATTTTCCACACTGACTAAAAG-3’) was 
added to the SPA bead suspension at a final concentration of 500nM and rocked 
at room temperature for one hour. The beads were washed twice with 1x 
Reaction Buffer by centrifugation at 1000 x g for five minutes. The SPA bead 
pellet was resuspended in 2x Reaction Buffer (with 20mM MgCl2) to a final 
concentration of 2mg/ml. Recombinant HIV-1 INWT was added to the amount of 
beads required for the experiment at a final concentration of 1µM and rocked for 
30 minutes at room temperature.  
2.3.3. The optimized SPA  
The SPA was carried out in 96-well microtiter plates (Perkin Elmer, USA) 
comprising of 50µl reactions per well. Each reaction consisted of 25µl of the 
prepared SPA bead-dDNA-IN complex, 50nM 3H-tDNA, 10µM test compound 
and was made up to 50µl with dH2O. DMSO replaced the test compound in the 
negative- and positive control. This reaction mixture was incubated at 22°C for 30 
minutes while shaking. Thereafter, ST reactions were initiated by adding 3H-tDNA 
to the reaction mixture at a final concentration of 50nM and incubated at 37°C 
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while shaking for 90 minutes. The enzymatic reaction was stopped with EDTA 
(without salt), a variable tested in section 2.3.1, at a final concentration of 62mM. 
The reaction product formation was subsequently measured in counts per minute 
(CPMs) using the Topcount NXT software version 2.54 on the Top Count 
scintillation counter NXT (Perkin Elmer, USA). 
The optimized SPA was used to screen the NCC compound library (Evotec, 
USA) and to conduct dose-response studies of cefixime trihydrate (CEF) and 
epigallocatechin gallate (EGCG). The optimized SPA was also used to screen 
CEF analogues against INWT. The CEF derivatives include: 7-
aminodesacetoxycephalosporanic acid (7-ADCA, Sigma Aldrich, USA), 7-
aminocephalosporanic acid (7-ACA, Sigma Aldrich, USA) and cephalothin 
sodium salt (CSS, Sigma Aldrich, USA). Mutation studies were conducted using 
the SPA where INWT was substituted with RAL resistant IN mutants, INQ148H and 
INQ148H/G140S that were previously prepared within our laboratories. DTG (Selleck 
Chemicals, USA) was used as a control. 
2.3.4. Handling of the Hamilton STARlet Robotic System 
Extensive training was undertaken on the Hamilton STARlet Robotic System 
(Hamilton Robotics, Switzerland) to gain experience and become familiar with 
operating and independent handling of the system. Training involved handling of 
the robotic system, programming protocols onto the system using the Hamilton 
method editor software version 4.2.0 7270 as well as troubleshooting of possible 
errors on the system.  
2.3.5. Amending the SPA onto the automated system  
A SPA protocol analogous to the optimized bench SPA was programmed on the 
automated system. To ascertain whether the automated SPA was on par with the 
manual SPA, dose-response experiments with RAL were conducted using the 
automated SPA and results thereof were compared with those obtained when 
conducting the manual SPA. 
2.3.6. Pooling of the NCC compound library 
In order to reduce cost and time, the NCC compound library was strategically 
pooled in an orthogonal method where one compound was present in two wells 
with different compounds (a row and a column pool).223 The Hamilton STARlet 
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robotic system was programmed to prepare the pooled compound dilution plates. 
Compounds were diluted to a final working concentration of 100µM in each pool. 
Figure 2.12 illustrates the assembly of pools comprised of eight or ten 
compounds. The eight-compound pools were comprised by combining an entire 
row of compounds from the NCC 96-well plates into a single well. The ten-
compound pools were comprised by combining the compounds of each column 
from the NCC 96-well plates into a single well. A total of 90 eight-compound 
pools and 72 ten-compound pools were generated.  
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Figure 2.12: A representative of the NCC 96-well compound plate illustrating the strategic 
orthogonal pooling of compounds. Pools were comprised of either eight- or ten compounds. The 
red oval demarcates the eight-compound pools constituted by combining the compounds of each 
column into a single well. The blue oval demarcates the ten compounds in a row that were 
combined to constitute the ten-compound pools. 
2.3.7. Screening of the NIH Clinical Collection 
The amended automated SPA was used to screen the prepared compound 
pools. Each automated experiment screened 18 pools (80 compounds). Overall, 
the entire NCC compound library consisting of 727 compounds was fully 
screened. 
2.4. Cell-based assays 
2.4.1. Cultivation of mammalian cells 
MT-4 cells (NIH AIDS Research and Reference Reagents Programme; Cat #120) 
were thawed at 37ºC and harvested in 20% growth media (Roswell Park 
Memorial Institute Medium 1640 (RPMI, Gibco, USA) containing 205mM L-
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glutamine (Thermo Fisher Scientific, USA) and supplemented with 20% 
inactivated fetal calf serum (FCS, Highveld Biologicals, SA), 20U/ml penicillin-
streptomycin (Gibco, USA) and 20µg/µl gentamycin (Gibco, USA). Cells were 
continuously sub-cultured every 2-3 days by centrifugation of the cell suspension 
at 360 x g for ten minutes and the subsequent pellet was resuspended in 10% 
growth media (RPMI 1640 media supplemented with 10% inactivated FCS, 
20µg/µl gentamycin and 20U/ml penicillin-streptomycin) for cell counting. Cells 
were counted by diluting the cell suspension 10x with 0.4% Trypan Blue stain 
(Gibco, USA) which cannot penetrate viable cells. The diluted cell sample was 
then added to the Countess Cell Counting Chamber Slide (Life Technologies, 
USA) and counted on the Countess Automated Cell Counter (Life Technologies, 
USA). Cells were then resuspended to 2 x 107 cells/ml in 10% growth media and 
incubated at 37ºC with 5% CO2. 
2.4.2. Cytotoxicity assays 
The protocol for the cytotoxicity assay was adapted from Mphahlele and co-
workers.224 Following sub-culturing and counting of cells, MT-4 cells were seeded 
at a final concentration of 1 x 105 cells/ml per well in 96-well plates. The cells 
were then incubated at 37ºC with 5% CO2 for one hour to stabilize. Dose-
response studies of CEF, EGCG and AMP were conducted using 2 fold serial 
dilutions with final concentrations ranging from 200µM to 1.56µM in 10% growth 
media. Auranofin (Biomol International, USA) was used as a control. These 
compound dilutions were added to the stabilized cells and incubated for four days 
at 37ºC with 5% CO2. The viability of the cells was determined using the Celltiter 
96 AQueous One Solution Cell proliferation assay (Promega, USA) that contains a 
tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS).225 The MTS solution was added to the cells at 
a volume of 10µl and incubated for two hours. Viable cells were quantified by 
measuring the reduction of the yellow tetrazolium dye in the MTS solution by 
metabolic active live cells to purple coloured soluble formazan. The absorbance 
of the formazan end-product was measured using the xMark spectrophotometer 
(Bio-Rad, USA) at 490nm.  
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2.4.3. HIV-1 phenotypic inhibition assay 
MT-4 cells were infected with HIV-1NL4-3 through spinoculation.
226 Briefly, following 
sub-culturing of the cells, the resuspended cells were seeded at a volume of 
100µl at a working concentration of 2 x 105 cells/ml in a 50ml conical tube. HIV-
1NL4-3 was added to the cell suspension at a 0.1 multiplicity of infection (MOI). 
Cells that were not treated with virus were used as the negative control. The cell 
suspensions were centrifuged for 90 minutes at 1186 x g. The supernatant was 
discarded and the pellet was washed thrice with 10% growth media and 
centrifugation at 1186 x g for 10 minutes. The cells were resuspended in 10% 
growth media at a concentration of 2 x 105 cells/ml and were seeded in 96-well 
microplates at a final concentration of 1 x 105 cells/well. The seeded cells were 
then incubated at 37ºC with 5% CO2 for one hour. Compounds were serially 
diluted to final concentrations ranging from 200µM to 1.56µM in 10% growth 
medium and added to the cells following the one hour incubation. The treated 
HIV-1 infected cells were then incubated for four days at 37ºC with 5% CO2. RAL 
and 118-D-24 were used as positive antiretroviral controls. To determine whether 
the EGCG, CEF and AMP had antiretroviral activity, a p24 detection assay was 
conducted using the Vironostika HIV-1 Ab/Ag ELISA kit (Biomerieux, France). 
Following the four day incubation, 15µl of the supernatant cells was transferred to 
p24 microplate wells that contained HRP-labelled anti-HIV-1 p24. The reaction 
mixture was then made up to 150µl with a premixed Specimen Dilution Buffer 
followed by a one hour incubation period at 37ºC. The reaction mixture was 
discarded and the wells were washed 7x with a 1x Wash Buffer (25x propriety 
mixed kit phosphate buffer concentrate diluted in phosphate buffered saline 
(PBS, 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4 and 1.8mM KH2PO4) for 30 
seconds per wash. A chromogenic substrate, tetramethylbenzidine (TMB) was 
then added to the wells. In the presence of the p24 antigen, the HRP enzyme 
linked to anti-HIV-1 p24 cleaves the TMB substrate subsequently producing a 
blue colour. The enzymatic reaction was terminated using 10% sulphuric acid 
and subsequently measured at 450nm using the xMark spectrophotometer.  
2.5. HIV-1 integrase ELISA 
An HIV-1 IN enzyme-linked immunosorbent assay was used as a secondary 
assay to validate the HITS identified through SPA screening. The protocol for this 
ELISA was extracted from Mphahlele and co-workers.224 Stock biotinylated dDNA 
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(section 2.3.2) was diluted to 150nM with 1x ELISA Buffer 1, pH 7.2 (20mM 
HEPES, 75mM NaCl, 4µM ZnCl2 and 2% glycerol). The diluted dDNA was added 
to streptavidin coated microplate wells (R & D Systems, USA) and incubated on a 
shaker at 25ºC for one hour. The wells were then washed thrice with PBS. 
Recombinant expressed HIV-1 INWT (section 2.1) was diluted to a final 
concentration of 1µM in ELISA Buffer 2 (ELISA buffer 1 with 5mM DTT and 
10mM MgCl2). The diluted IN was then added to the microplate wells and 
incubated at 22ºC for 30 minutes. The negative control did not contain IN. The 
unbound IN was aspirated and the wells were washed 2x with 1x PBS for five 
minutes at 25ºC. The compound stock solutions were diluted to a working 
concentration of 10mM in DMSO. The test compounds were diluted to 100µM or 
10µM in ELISA Buffer 2 and added to the wells followed by a 30 minute 
incubation period at 37ºC. DMSO substituted the test compounds in the negative- 
and positive control. Annealed tDNA (5’-TGACCAAGGGCTAATTCACT-3’ 
fluorescein and 5’- AGTGAATTAGCCCCTTGGTCA-3’ fluorescein) (Inqaba 
biotech, South Africa) was added to the wells at a final concentration of 250nM 
and the mixture was incubated for an additional hour at 37ºC. The tDNA and 
unbound compounds were aspirated and the wells were then washed 3x with 2x 
saline sodium citrate (SSC) buffer pH 7 (0.15M Na3C6H5O7 and 1.5M NaCl) for 10 
minutes at 25ºC. Rabbit anti-fluorescein isothiocyanate (FITC): HRP antibody 
(AbD Serotech, UK) was diluted 1:10 000 in 1x PBS and added to each well. The 
wells containing the antibodies were incubated for 1-2 hours at 22ºC and were 
transferred to 4ºC for an overnight incubation. Following the overnight incubation, 
the antibodies were aspirated and the wells were washed 3x with 1x PBS for 10 
minutes at 22ºC. Sureblue TMB microwell peroxidase substrate (KPL, USA) was 
added to each well and the reaction was incubated at 37ºC for 15-30 minutes. In 
the presence of an HRP labelled conjugate, the reaction turns blue which was 
measured at 620nm using the xMark spectrophotometer.  
2.6. Reverse transcriptase activity colorimetric assay 
The effect of CEF, EGCG and AMP on RT activity was determined using the 
colorimetric Reverse Transcriptase Assay kit (Roche Diagnostics, Switzerland). 
The assay is based on a typical sandwich ELISA method and was carried out 
according to the kit instructions. All reagents used in the assay were provided 
with the kit. The reagents in the kit were prepared as follows: the nucleotide 
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mixture was prepared by diluting the nucleotide, digoxigenin (DIG)-dUTP, biotin-
dUTP and dTTP, 10x with Incubation Buffer, pH 7.8 (50Mm Tris Buffer with 
319mM KCl, 33mM MgCl2 and 11mM DTT). The reaction mixture was prepared 
by adding the primer template to the 10x prepared nucleotides at a final 
concentration of 0.9 A260/ml. The lyophilized anti-DIG-peroxidase (anti-DIG-POD) 
was prepared by reconstituting the antibody in dH2O to a final concentration of 
20U. The working dilution of anti-DIG-POD was prepared by diluting the 
reconstituted antibody to a final concentration of 200mU/ml with Conjugate 
Dilution Buffer (sodium phosphate buffer pH 7.4 containing a blocking reagent). 
The 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate 
was prepared by dissolving one ABTS tablet in Substrate Buffer (NaBO3•nH2O 
and citric acid/phosphate buffer). Sample mixtures were prepared in separate 
tubes for each test compound at a final volume of 60µl. Each sample comprised 
5 nanograms (ng) HIV-1 RT, 100µM or 10µM test compound, 20µl reaction 
mixture and the sample mixture was made up to 60µl with RT Lysis Buffer pH 7.8 
(50mM Tris, 80mM KCl, 2.5mM DTT, 0.75mM EDTA and 0.5% Triton X-100). 
The test compound in the positive control was replaced with RT Lysis Buffer. The 
negative control did not contain RT enzyme and was replaced with RT Lysis 
Buffer. AZT-triphosphate (TP) (GeneCraft, UK) was used as a control compound. 
The sample mixture was then incubated at 37ºC for one hour. After the 
incubation period, the sample mixtures were transferred to the streptavidin 
coated microplate modules and then further incubated for one hour at 37ºC. The 
sample mixtures were then removed from the wells followed by washing of the 
wells with the premixed kit Washing Buffer 5x for 30 seconds per wash at room 
temperature. The anti-DIG-POD was added to each well at a working dilution of 
200mU/ml and incubated for one hour at 37ºC. The wells were then washed 5x 
with the premixed kit Washing Buffer for 30 seconds per wash at room 
temperature. The ABST substrate was added to each well at a final volume of 
200µl and incubated at room temperature for 15 minutes. The absorbance of the 
green/blue colour was measured at 405nm. 
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2.7. Virtual screening of cefixime trihydrate and 
epigallocatechin gallate 
2.7.1. In silico evaluation of some ADME descriptors of cefixime 
trihydrate and epigallocatechin gallate 
The structures of CEF and EGCG were obtained from the standard database 
format (SDF) file on www.nihclinicalcollection.com for ADME studies using Osiris 
Property Explorer and Discovery Studio Software.154 The online software, Osiris 
Property Explorer (www.organic-chemistry.org/prog/peo/), was used to calculate 
drug-relevant properties such as the logarithm partition coefficient (cLogP), 
aqueous solubility (LogS) and drug score. The cLogP of a compound is a 
measure of the hydrophilicity of a compound. High cLogP values are indicative of 
low hydrophilicity and are associated with poor absorption and permeation. The 
LogS of a compound modulate the absorption and distribution of a compound 
where low solubility compounds are associated with poor absorption. The drug 
score of a compound is a single value that describes the overall potential of a 
compound as a drug. ADME descriptors such as absorption (HIA and aqueous 
solubility) and distribution (BBB penetration) properties of CEF and EGCG were 
predicted using the ADME Descriptor tool in the Discovery Studio version 3.1 
software (Accelrys, USA). The cLogP of CEF and EGCG used in Lipinski Ro5 
characterizations were retrieved from Osiris Property Explorer. The MW of the 
compounds and hydrogen donors and acceptors were retrieved from the SDF file 
on www.nihclinicalcollection.com.   
2.7.2. Molecular modelling of cefixime trihydrate and 
epigallocatechin gallate 
An HIV-1 IN monomer structure attached to viral DNA was previously prepared 
within our laboratory and was used in molecular docking simulations using 
Discovery Studio software version 3.1 (Accelrys, USA). The protein was 
automatically prepared for docking by inserting missing atoms, modifying missing 
loop regions and removing disorderly conformations. A binding site within a 
protein cavity defining a specific area where binding interactions may occur was 
created by selecting residues within a 7 angstrom (Å) radius surrounding the 
Mg2+. The small molecules of the NCC library were prepared using the Prepare 
Ligand Tool that generated isomers and tautomers and removed duplicate ligand 
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structures and ligands with undesirable properties. The structures of the control 
compounds RAL, EVG and DTG were obtained from the protein data bank 
(www.rcsb.org/pdb) and prepared using the prepare ligand tool. The LibDock tool 
was used to generate multiple conformations of the prepared ligands using the 
BEST conformation method. These conformations were then docked by locating 
the hotspots in the receptor binding site consequently generating numerous 
poses per ligand conformation. Poses with the best LibDock scores were 
selected for further optimization. The grid based CDOCKER tool that utilizes a 
CHARMm force field was used to refine the poses of the ligand by keeping the 
receptor binding site rigid whilst the ligands are more flexible. Thereafter, the 
scores of the refined poses, obtained from the CDOCKER, were calculated to 
select the best representative score that is indicative of the receptor-ligand 
interactions. 
 
2.8. Data analysis 
Microsoft Excel 2010 was used to calculate all averages and standard deviations 
(SD) as well as to construct bar- and pie graphs. Percentage inhibition was 
calculated using the following equation:  
 
Where testI represents the endpoint value of the inhibitor, neg the endpoint value 
of the negative control and pos the endpoint value of the positive control. p-
values were calculated to assess statistical differences within parameters and 
assay conditions. This was done using the online pairwise t-test 
(www.quantitativeskills.com/sisa/). Origin software version 6.1 (OriginLab, USA) 
was used to calculate the IC50, cytotoxicity change at 50% cytotoxic concentration 
(CC50) and the half maximal effective concentration (EC50) of the compounds. 
Origin software was also used to construct sigmoidal curves and to calculate the 
Hill-Slope of the curves. The FCIC50 values of inhibitors in mutation studies were 
calculated by dividing the IC50 of an inhibitor against a mutant integrase by the 
IC50 of an inhibitor against WT integrase. The Z-factor, used to describe the 
quality of the SPA, was calculated using an online calculator (www.screeningunit-
fmp.net/tools/z-prime.php).  
CHAPTER 3 
Results 
 
39 
 
 
3.1. Expression and purification of recombinant wild type HIV-
1 subtype B integrase 
Recombinant HIV-1 INWT was successfully expressed in E.coli after a three hour 
incubation at 37°C when induced with 1mM IPTG. Recombinant expressed INWT 
was verified on an SDS-PAGE (Figure 3.13) and compared to a positive- and 
negative control. The positive control was a recombinant HIV-1 IN received from 
the NIH while the negative control comprised E.coli BL21 pINSD.His that was not 
induced with 1mM IPTG. The expressed INWT was observed at its expected size 
of approximately 32kDa, which also corresponded with the positive HIV-1 IN 
control. No expressed INWT protein was observed in the negative control.  
 
                   
 
Figure 3.13: SDS-PAGE depicting the pINSD.His gene expression in E. coli BL21 after 
induction with 1mM IPTG. The samples were analysed alongside Protein Mr Weight Markers (Bio-
Rad, USA) that aid in determining the size of the expressed recombinant HIV-1 integrase. The 
SDS-PAGE was visualized using a Coomassie stain and the image was captured on the MiniBIS 
Pro gel capture imager. Lane 1 contained the positive control; Lane 2 contained the recombinant 
proteins expressed after induction with 1mM IPTG where the arrow indicates the protein that was 
predominantly expressed at the estimated size of 32kDa; Lane 3 contained the negative control 
(E.coli BL21 pINSD.His cells that were not induced with 1mM IPTG) where no bands were 
prominently expressed. Molecular weights in kDa, are indicated on the left. 
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After clarification of the 1mM IPTG induced crude extract, the pellet was 
discarded because it contained insoluble proteins and was therefore not used for 
further purification (data not shown). The supernatant, expected to contain the 
soluble recombinant INWT, was loaded onto the Ni-affinity column for purification.  
Figure 3.14 illustrates the elution profile of INWT from the Ni-affinity column at a 
gradient where Wash Buffer 2 (150mM imidazole) was the starting buffer and 
Elution Buffer (600mM imidazole) was the final buffer. The peak observed 
between fraction 14 and 23 is representative of the eluted INWT.  
        
 
 
Figure 3.14: Elution profile depicting the elution of the His-tagged proteins from the Ni-
affinity column. The blue, green, red, light blue and brown lines denote UV absorbance, imidazole 
concentration, conductivity, temperature and pressure, respectively. The elution profile, extracted 
from the ÄKTA Primeview 2 software, exemplified the elution of His-tagged proteins by measuring 
the UV absorbance of proteins per fraction (3ml/fraction) at a flow rate of 1ml/min for 3 minute 
intervals. A peak comprised of fractions 14 to 22 was observed during the elution period between 
39- and 63 minutes. 
The fractions (14-22), corresponding to the peak (Figure 3.14), were pooled and 
separated from other buffer components through ultra-filtration in order to 
increase the protein concentration. Recombinant expressed His-tagged protein 
samples were collected after each purification and concentration step to analyse 
the purity and intensity thereof through SDS-PAGE, as illustrated in Figure 3.15. 
Fraction per time (minutes) 
U
V
 A
b
s
o
rb
a
n
c
e
 (
n
m
) 
 
 
Fraction number over time (minutes) 
U
V
 A
b
s
o
rb
a
n
c
e
 (
2
8
0
n
m
) 
 Results 
 
41 
 
The recombinant expressed proteins were observed at approximately 32kDa 
which aligned with the positive control. The intensity of the bands depicted by the 
arrow in Figure 3.15, increased after Ni-affinity chromatography, ultra-filtration 
and PD-10 Sephadex size exclusion chromatography where each band 
demonstrated intensity of 145 298, 142 0994 and 196 839 after each step, 
respectively. The percentage purity of the recombinant proteins observed at 
approximately 32kDa was 73%, 70% and 77% after Ni-affinity chromatography, 
ultra filtration and size exclusion chromatography, respectively. Additional bands 
were observed between 50-75kDa. 
                   
 
               
  
 
Figure 3.15: SDS-PAGE depicting the purity and intensity of the recombinant expressed 
proteins. Samples were analysed alongside Protein Mr Weight Markers and verified using a 
recombinant HIV-1 integrase (IN) as a positive control. The gel was stained with Coomassie stain 
and visualized on the gel capture imager. Lane 1 contained the positive control; Lane 2 contained 
the E.coli BL21 pINSD.His after induction with 1mM IPTG; Lane 3 contained the crude extract after 
centrifugation; Lane 4 contained the fractions eluted from the Ni-affinity column; Lane 5 contained 
the concentrated His-tagged proteins using the Millipore ultra-filtration vacuum; Lane 6 contained 
the His-tagged protein after it was buffer exchanged into Storage Buffer using the PD-10 Sephadex 
column. The arrow denotes that the over-expressed recombinant protein was at the size (32kDa) at 
which INWT is expected. Additional protein bands were observed in lanes 4-6 between 50-75kDa. 
Molecular weights, in kDa are indicated on the left.   
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Intensity 145 298 142 0994 196 839 
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The presence of the recombinant His tagged protein was confirmed by a Western 
blot probed against the His-tag (using anti-His primary antibodies) (Figure 3.16 A) 
on the recombinant expressed INWT. The presence of recombinant INWT was 
further verified by stripping and re-probing the PVDF membrane with HIV-1 HXB2 
IN antiserum (Figure 3.16 B). The bands observed on the Western blot probed 
with anti-His primary antibodies correlated with the Western blot probed with IN 
antiserum. The bands detected also correlated with the HIV-1 IN positive control. 
           
A                 B 
Figure 3.16: Western blot probed with A - anti-His and B - anti-integrase primary antibodies 
verifying the expression of INWT. The Western blot images were visualized by means of 
chemiluminescence. The presence of recombinant expressed INWT was verified using a positive 
control HIV-1 integrase (IN). The presence of the recombinant expressed INWT was detected using 
antibodies against the His-tag on the recombinant expressed INWT as well as antibodies against the 
HIV-1 IN protein itself. Lane 1 contained the positive control; Lane 2 contained the pooled fractions 
(14-23) eluted from the Ni-affinity column; Lane 3 contained the concentrated INWT through ultra-
filtration; Lane 4 contained INWT after it had been buffer exchanged into Storage Buffer using the 
PD-10 Sephadex column. An additional band was observed that is demarcated with a white circle 
while the arrows denote recombinant INWT and positive control. 
3.2. SPA screening  
3.2.1. Purification of the radiolabeled (3H) target DNA 
Radiolabeled tDNA, 3H-tDNA, was purified to remove unincorporated nucleotides. 
The absorbance spectrum of the 3H-tDNA was extracted from the Nanodrop 
installation version 1.3.1 software where Figure 3.17 exemplifies the absorbance 
spectrum. A peak was observed at 260nm, the wavelength at which pyrimidines 
and purines of nucleic acids absorbs UV light. The purified DNA yielded a nucleic 
absorbance ratio of A260/A280 = 1.85 which is in the pure DNA ratio range. 
1        2          3           4                  1         2          3         4        
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Figure 3.17: The absorbance spectra of the 
3
H-tDNA extracted from the Nanodrop 
installation version 1.3.1 software obtained when quantifying the 
3
H-tDNA concentration 
using the Nanodrop spectrophotometer.  Absorbance was read at a wavelength ranging from 
220nm-345nm where a peak was observed at 260nm with a maximum < 1.05. 
3.2.2. Optimization of the HIV-1 integrase SPA 
The fundamental SPA protocol was extracted from Grobler and co-workers203 
where several parameters were modified such as the reaction buffer, metal 
cofactors and stop solutions. The optimal conditions were determined using the 
percentage ST inhibition attributed to RAL, the CPM signal and the Z-factor of the 
assay.  
The Z-factor of an assay is usually within a -1 < Z ≤ 1 range. When there is no 
data variation (SD = 0), and Z = 1, the assay is termed “ideal”. When the 
separation band is large (1 > Z ≥ 0.5), the assay is termed “excellent”. The assay 
is termed “marginal” when the separation band is low (0.5 > Z > 0). When there is 
no separation band between the positive- and negative control, the assay is not 
useful for screening.227 
Since the catalytic activity of HIV-1 IN is modulated by metal cofactors in the DDE 
motif of the IN active site, the optimal metal cofactor was determined by 
conducting experiments with MgCl2 and MnCl2. When comparing the CPM signal 
of the postive controls when conducting experiments using MgCl2 and MnCl2, 
MgCl2 rendered a higher CPM signal (97.5 ± 0.7) compared to experiments 
conducted with MnCl2 (78 ± 17.1). When comparing IN ST inhibition due to RAL, 
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experiments using MgCl2  demonstrated a significantly higher inhibition (65 ± 
15%, p = 0.02) compared to experiments conducted with MnCl2 (31 ± 8.5%). 
Figure 3.18 compares the IN ST inhibition attributed to RAL when experiments 
were conducted using MgCl2 and MnCl2. The Z-factor of the experiments, when 
using MgCl2 and MnCl2, were 0.952 and 0.497, respectively. MgCl2 was 
considered as the optimal metal chelator as it rendered the highest IN inhibition 
and the higher CPM signals and had the highest Z-factor when compared to 
MnCl2.  
 
Figure 3.18: Comparison of the percentage integrase (IN) strand transfer (ST) inhibition 
caused by raltegravir (RAL) when conducting experiments with metal cofactors, MgCl2 and 
MnCl2. SPA experiments using  MgCl2 demonstrated 65 ± 15% IN ST by RAL where experiments 
using MnCl2 only inhibited IN ST by 31 ± 8.5%. The asterisks indicate that the % IN ST in the 
presence of MgCl2 is significantly different from that of MnCl2. The error bars indicate the SD of the 
mean average of at least three experiments. 
To increase the CPM signal of the SPA, several reaction buffers, obtained from 
literature, were tested. The highest CPM signal was observed when using Buffer 
4 (278 ± 91.85), however the Z-factor (-0.277) was the lowest when compared to 
the Z-factor of the experiments conducted using Buffer 1, 2 and 3, respectively. 
The highest IN ST inhibition was observed when using Buffer 2 (85 ± 10%) which 
also rendered the highest Z-factor (0.445).  
Table 3.1 compared the reaction buffers and its effect on the CPM signal, the IN 
ST inhibition attributed to RAL as well as the Z-factor of the assay. The highest 
* 
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CPM signal was observed when using Buffer 4 (278 ± 91.85), however the Z-
factor (-0.277) was the lowest when compared to the Z-factor of the experiments 
conducted using Buffer 1, 2 and 3, respectively. The highest IN ST inhibition was 
observed when using Buffer 2 (85 ± 10%) which also rendered the highest Z-
factor (0.445).  
Table 3.1: Comparison of the different reaction buffers tested in the SPA and its effect on the 
CPM signal, integrase strand transfer inhibition and the Z-factor of the assay.  
Buffer 
CPM signal ± 
SD 
(Positive 
control) 
CPM signal 
± SD 
(Positive 
control) 
Percentage 
integrase 
strand transfer 
inhibition ± SD 
(Raltegravir) 
Z-factor 
1 83 ± 19 11 ± 1.41 65 ± 0.17 0.22 
2 141 ± 49 13 ± 4.95 85 ± 10 0.45 
3 92 ± 7.41 17 ± 9.59 78 ± 12.2 0.20 
4 278 ± 91.85 21 ± 8.88 70 ± 4.3 -0.28 
 
The optimal stop solution was determined by terminating the reaction between IN 
and 3H-tDNA with different stop solutions. When comparing the CPM signal of the 
positive controls after the addition of the stop solutions, Stop Solution 3 
demonstrated the lowest positive control CPM signal (305 ± 29) as opposed to 
reactions stopped with Stop Solution 2 that had the highest CPM signal (589 ± 
39). The reaction terminated with Stop Solution 2 yielded a CPM signal of 484.5 ± 
16) for the positive control. RAL inhibited IN ST by 88 ± 4%, 74 ± 2% and 56 ± 
17% when the SPA enzymatic reactions were stopped with Stop Solution 1, 2 
and 3, respectively (Figure 3.19). RAL demonstrated no appreciable IN ST 
inhibition (0.209 ± 0.03%) when the reaction was not stopped.  
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Figure 3.19: Comparison of the integrase (IN) strand transfer (ST) inhibition by raltegravir 
(RAL) after the enzymatic reaction between IN and 
3
H-tDNA was terminated with different 
stop solutions: Stop Solution 1 (62mM EDTA), Stop Solution 2 (62mM EDTA with 63mM NaOH) 
and Stop Solution 3 (62mM EDTA with 63mM NaOH and 2.5M CsCl). The highest IN ST inhibition 
was observed when stopping the reaction with Stop Solution 1 (88 ± 4%) followed by Stop Solution 
2 (73 ± 3%) and Stop Solution 3 (56 ± 3%). The reaction that was not stopped demonstrated no 
appreciable IN ST inhibition (0.209 ± 0.03%). Error bars indicate the standard deviation within 5% 
of the mean of triplicate data. 
3.2.3. Validating the optimized SPA with known integrase inhibitors 
The optimized SPA was validated using known controls and inhibitors such as 
RAL, EVG, 118-D24 and AZT. Dose response studies of RAL, EVG and 118-D24 
were conducted subsequently determining their IC50 values. Figure 3.20 
represents the dose-dependent response of RAL, EVG and 118-D24. The IC50 
values obtained were 9.98 ± 0.83nM, 4 ± 1.04nM and 1.50 ± 0.81µM for RAL, 
EVG and 118-D24, respectively and were compared to literature to validate the 
authenticity of the optimized SPA. The results obtained correlated with 
documented IC50 values of RAL, EVG and 118-D24 which have been reported as 
7nM, 8.80nM and 1.53µM, respectively.110,222,228 AZT was used as the negative 
control where no IN inhibition was observed. The Z-factor of this experiment, 
0.93, further validated the quality of the SPA. 
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Figure 3.20: Representative sigmoidal curves of raltegravir (RAL), elvitegravir (EVG) and 
118-D24 obtained when conducting dose-response studies using an integrase inhibition 
SPA. Each point indicates the normalized average mean of triplicate results and its standard 
deviation within 5% of the mean. The Hill-Slope variable describes the slope of the curve. The 
sigmoidal curve of 118-D24 demonstrates a standard sigmoid dose-response curve with a Hill-
Slope close to -1. The slope of RAL and EVG are more shallow than the slope of 118-D24. The 
area under curve for RAL and EVG decreased with an increase in IC50. 
3.2.4. HIV-1 integrase SPA amended to the automated system 
A SPA protocol analogous to the optimized SPA was programmed onto the 
Hamilton Robotic STARlet System. The automated assay was validated by 
conducting a dose-response study using RAL and comparing the IC50 of RAL 
obtained when using the automated assay to the RAL IC50 obtained when using 
the manual assay. Figure 3.21 compares the sigmoidal curve of RAL obtained 
when conducting the automated SPA and when conducting the manual SPA. The 
IC50 of RAL obtained when using the automated SPA was 7.30 ± 0.35nM which 
was not significantly different from the IC50 of RAL when using the manual SPA (p 
= 0.99). It was also observed that the Z-factor obtained when conducting the 
manual SPA (0.96) was slightly higher than the Z-factor obtained when 
conducting the automated SPA (0.88), however not significantly different (p = 
0.85). 
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Figure 3.21: The sigmoidal curves depict the comparison between the raltegravir (RAL) 
dose-dependent response (0.001µM to 10µM) when using the automated SPA and the 
manual SPA. The IC50 of RAL when using the automated SPA was 7.3 ± 0.35nM which correlated 
with the IC50 = 9.98 ± 0.83nM (p = 0.99) obtained when using the manual SPA. The Hill-Slope for 
the automated SPA was -0.6 whereas the manual SPA demonstrated a Hill-Slope of -1.46 
indicating that the manual SPA curve is steeper with a higher IC50 value than the sigmoidal curve 
for the automated SPA. 
3.2.5. Screening of the NCC library 
Before the compounds in the NCC compound library were screened, they were 
diluted to a final working concentration of 100µM in their respective pools with 
DMSO. To validate whether the pooling method would be suitable in a SPA, 
10µM of RAL was added to two random pools containing eight and ten 
compounds, respectively. Pools that included 10µM RAL were compared to pools 
without RAL to determine if RAL in the presence of eight or ten other compounds 
inhibited IN ST. RAL maintained its inhibitory effect by inhibiting IN ST by 89 ± 
4% within the eight-compound pool and 90 ± 3% within the ten-compound pool.  
The entire NCC was evaluated by screening one NCC plate, containing 80 
compounds (18 pools), per experiment. A total of 171 pools comprising 727 
compounds in the NCC compound library were tested. Figure 3.22 is a 
summation of the percentage IN ST inhibition of each compound pool.  Amongst 
the 171 pools, 136 pools demonstrated 0-10% IN ST inhibition, six pools 
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demonstrated 10-50% IN ST, three pools demonstrated 50-80% IN ST inhibition 
and one pool yielded IN ST inhibition > 80%. The remaining 25 pools were 
undefined due to the colour of the compounds that may have influenced the CPM 
signal thus resulting in false positives.  
 
Figure 3.22: Pie chart representation of the screened NCC pools according to their 
percentage integrase (IN) strand transfer (ST) inhibition. A total of 171 pooled compounds were 
screened in an orthogonal method where each compound was present in at least two pools. 
Amongst the 171 pools, 136  had approximately 0-10% IN ST inhibition compared to only one pool 
that demonstrated IN ST inhibition exceeding 80%. Furthermore, only six pools showed IN ST 
inhibition between 10-50% and three pools demonstrated IN ST inhibition between 50-80%. 
Compounds that influenced the CPM signal through quenching were deemed undefined. 
The compounds comprising pools that demonstrated IN ST inhibition > 50%, 
were tested individually on the SPA to identify the compound responsible for the 
IN ST inhibition. A Cephalosporin Beta (β)-lactam antibiotic, CEF, and an 
antioxidant found in Green Tea, EGCG, were identified as the compounds that 
attributed to the IN ST inhibition.  
3.2.6. Dose response studies of cefixime trihydrate and 
epigallocatechin gallate 
Dose-response studies of CEF and EGCG were conducted to determine the 
concentration of compound required for 50% IN ST inhibition. IC50 curves were 
constructed using the optimized SPA and the IC50 values of CEF and EGCG 
 Results 
 
50 
 
against INWT were determined. The IC50 values were 6.03 ± 1.29µM and 9.57 ± 
1.62µM for CEF and EGCG, respectively, as depicted in Figure 3.24.  
3.2.7. Integrase resistant mutation profiles of cefixime trihydrate and 
epigallocatechin gallate 
The activity of INWT and RAL induced mutants, INQ148H and INQ148H/G140S, was 
determined using the optimized SPA. The activity of the enzyme was determined 
using the CPM signal of the positive control for INWT, INQ148H and INQ148H/G140S. 
The activity of INQ148H decreased 6 fold (CPMs for INWT = 220 and INQ148H = 34 
with background CPM = 18) whereas the activity of INQ148H/G140S decreased 2.6 
fold (INWT = 311 and INQ148H/G140S = 117 with background CPM = 15). RAL, EVG 
and DTG were used as controls against INQ148H/G140S. The sigmoidal curves of the 
RAL, EVG and DTG dose-response studies are demonstrated in Figure 3.23. 
INQ148H/G140S demonstrated resistance to the known inhibitors with IC50 values of 
1.5 ± 0.50µM and 2 ± 0.20µM obtained with RAL and EVG, respectively. These 
findings  were comparable to previously documented IC50 values of 1.96µM and > 
1 obtained for RAL and EVG respectively against this integrase mutant.229,230 The 
FCIC50 of RAL and EVG was 214 and 200, respectively. INQ148H/G140S mutation 
demonstrated no appreciable resistance to DTG (IC50 = 3 ± 1nM). 
  
Figure 3.23: The sigmoidal curves demonstrate the dose-response studies of dolutegravir 
(DTG), raltegravir (RAL) and elvitegravir (EVG) controls against HIV integrase (IN) 
harbouring the Q148H/G140S mutation. DTG did not exhibit a sigmoidal curve and generated a 
steep Hill-Slope of -4. EVG demonstrated a standard sigmoid dose-response curve with a Hill-
Slope of -1. RAL demonstrated a steeper curve than EVG with a Hill-Slope of -3.  
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Figure 3.24 represents the dose-response studies of CEF and EGCG conducted 
to determine the IC50 of the HITS against INQ148H/G140S mutation. The IC50 for CEF 
and EGCG were 5.01 ± 0.3µM and 0.619 ± 0.5µM respectively, with FCIC50 
values of 0.8 and 0.065. 
   
A            B 
Figure 3.24: The dose response curves of A: Cefixime trihydrate (CEF) and B: 
Epigallocatechin gallate (EGCG) exemplifying their IC50 values when screening against HIV 
integrase wild type (INWT) and INWT harbouring the Q148H/G140S mutation. The IC50 of CEF 
and EGCG screened against INWT were 6.03 ± 1.29µM and 9.57 ± 1.62µM, respectively. The IC50 
values obtained when screening CEF and EGCG against the INQ148H/G140S were 5.01 ± 0.3µM and 
0.619±0.5µM, respectively. The curves represent experimental data in triplicate with error bars 
within a standard deviation of 5% of the mean. The slope of both CEF and EGCG against 
INQ148H/G140S are shallower than the slopes of CEF and EGCG against HIV-1 INWT. The IC50 values 
of CEF and EGCG against INQ148H/G140S and INWT increase as the area under the curve decrease. 
3.2.8. Screening of cefixime trihydrate derivatives 
The CEF derivatives, 7-ADCA, 7-ACA and CSS containing the distinct β-lactam 
ring (Figure 3.25), were screened against INWT using the SPA to identify the 
moiety on the CEF structure that attributed to the IN ST inhibition. 7-ADCA, 7-
ACA and CSS at 10µM yielded 2.45 ± 1.08%, 1.9 ± 1.46% and 5.28 ± 12.10% IN 
ST inhibition, respectively. In addition, a closely related β-lactam antibiotic, AMP 
(Figure 3.25), was screened against INWT and demonstrated 66.5 ± 1.44% IN ST 
inhibition at 10µM. 
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A     B 
 
C     D 
 
E 
Figure 3.25: The structures of cefixime trihydrate and its structurally related compounds. A - 
Cefixime trihydrate (CEF) B - 7-aminodesacetoxycephalosporanic acid (7-ADCA) C - 7-
aminocephalosporanic acid (7-ACA) D - Cephalothin sodium salt (CSS) E – Ampicillin (AMP). The 
β-lactam rings, consistent in all structures, are demarcated with the red blocks. Structures obtained 
from www.chemspider.com, accessed 19/09/2013. 
3.2.9. Further development of identified HIT compounds 
3.2.9.1. Evaluating the cytotoxicity of epigallocatechin gallate, 
cefixime trihydrate and ampicillin 
The cytotoxicity of CEF, EGCG and AMP in MT-4 cells was tested and CC50 
values were determined. CEF and AMP did not demonstrate toxicity (CC50 > 
200µM) within the range evaluated. The dose-response sigmoidal curve of EGCG 
is demonstrated in Figure 3.26. EGCG yielded a CC50 of 23 ± 1µM whereas 
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previous studies reported that EGCG did not demonstrate cytotoxicity at a 
concentration < 100µM in peripheral blood mononuclear cells.231 The control, 
auranofin, had a CC50 = 0.57 ± 0.16µM which correlated with a previously 
reported CC50 value for auranofin (CC50 < 1.652µM).
232 
 
Figure 3.26: A representation of the dose-response studies of epigallocatechin gallate to 
determine the cytotoxicity of the compound in MT-4 cells. The viability of the cells was 
quantified through an MTS assay where the absorbance of the reduced formazan product was read 
at 490nm. The sigmoidal curve demonstrates the concentration that reduces cell viability by 50% 
(CC50 = 23 ± 1µM). A steep curve is observed with a Hill-Slope of -24. Each datapoint is the 
average of triplicate experiments with errors bars indicating the standard deviation of the average 
mean within 5%.  
3.2.9.2. Determining the effect of cefixime trihydrate, epigallocatechin 
gallate and ampicillin on reverse transcriptase activity 
CEF and EGCG were screened against RT to determine whether the compounds 
had an effect on RT activity. The absorbance value of the ABTS-peroxidase end-
product was indicative of RT activity. Figure 3.27 represents the absorbance 
value of each compound tested as well as the absorbance values of the controls. 
EGCG inhibited RT activity by 56% and 25% at 100µM and 10µM, respectively. 
CEF inhibited RT activity by 14% and 9% at 100µM and 10µM, respectively. AMP 
inhibited RT activity by 8% and 1% at 100µM and 10µM, respectively. It is evident 
that the effect of EGCG on RT activity was dose-dependent. 
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Figure 3.27: Representation of the absorbance values measured at 405nm when analysing 
the effect of cefixime trihydrate (CEF), epigallocatechin gallate (EGCG) and ampicillin (AMP) 
on reverse transcriptase (RT) activity. The absorbance values of CEF, AMP and EGCG (10µM) 
was not significantly lower than the absorbance value of the positive control (p > 0.05). The 
absorbance value of EGCG at 100µM was significantly lower than the absorbance value of the 
positive control (p = 0.023) indicating inhibition of RT activity. The AZT-tp control absorbance value 
was significantly lower than the positive control (p = 0.002). The asterisks (*) signify statistical 
differences.  
3.2.10. Orthogonal screening of the identified HITS 
3.2.10.1. Validation of the cefixime trihydrate and epigallocatechin 
gallate through HIV-1 IN ELISA  
The effect of CEF, EGCG and AMP against INWT ST activity was confirmed 
through an HIV-1 IN ELISA. Figure 3.28 represents the absorbance values 
obtained for CEF, EGCG, AMP and RAL. CEF demonstrated 21% and 15% ST 
inhibition at 100µM and 10µM, respectively. EGCG exhibited 29% and 26% ST 
inhibition at 100µM and 10µM, respectively. AMP inhibited ST activity by 53% 
and 27% at 100µM and 10µM, respectively. RAL at 10µM was used as a control 
and exhibited 97% IN ST inhibition. 
* 
* 
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Figure 3.28: The absorbance readings (A620) measured when conducting an HIV-1 integrase 
(IN) ELISA to confirm the IN strand transfer (ST) inhibitory effect of cefixime trihydrate (CEF), 
epigallocatechin gallate (EGCG) and ampicillin (AMP). The A620 measured was directly 
proportional to the ST activity. Although the absorbance values of CEF, EGCG at 100µM and 10µM 
were lower than the positive control, they were not significant (p > 0.05). The AMP absorbance 
value at 100µM was significantly lower than the positive control (p = 0.01). The absorbance values 
observed for AMP was dose-dependent since the absorbance values decreased with an increase in 
compound concentration. The raltegravir control absorbance values were significantly lower than 
the positive control (p = 0.0004). The asterisks (*) represent statistical differences. 
3.2.10.2. Further validation of cefixime trihydrate, epigallocatechin 
gallate and ampicillin through an HIV-1 phenotypic inhibition 
assay 
Phenotypic assays were conducted to further validate the effect of CEF, EGCG 
and AMP against HIV-1. The activity of the virus was determined by detecting the 
p24 expression within infected MT-4 cells. Figure 3.29 represents the absorbance 
values measured for each compound tested as well as the controls. EGCG at 
200µM demonstrated viral activity inhibition > 100% whereas CEF and AMP at 
200µM demonstrated viral activity inhibition of 23% and 51%, respectively. RAL 
inhibited viral actvity by 74% at 100nM and 118-D-24 at 100µM inhibited viral 
activity by 97%.  
* 
* 
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Figure 3.29: The absorbance values of cefixime trihydrate (CEF), epigallocatechin gallate 
(EGCG), ampicillin (AMP) and the controls measured at 450nm when detecting the level of 
p24 expression in an HIV-1 phenotypic assay. The absorbance value of EGCG, AMP, 118-D-24 
and RAL were significantly lower than the positive control (p < 0.05). The asterisks (*) indicate 
statistical differences.  
Dose-dependent studies of EGCG and the control, 118-D-24, yielded EC50 values 
of 24 ± 3µM and 9 ± 4µM, respectively. Previous phenotypic studies have 
reported EC50 values of 730nM and 2.1µM for EGCG and 118-D24, 
respectively.222,233 Figure 3.30 exemplifies dose-dependent response curves of 
EGCG and 118-D-24. 
 
* 
* * 
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Figure 3.30: Sigmoidal curves representing the dose-dependent inhibition of p24 expression 
attributed to epigallocatechin gallate (EGCG) and the control 118-D-24 in HIV-1 infected MT-4 
cells. EGCG exhibited an EC50 = 24 ± 3µM and 118-D24 an EC50 = 9 ± 4µM. The Hill-Slope of 118-
D24 demonstrates a standard sigmoid dose-response curve with a Hill-Slope of close to -1. The 
slope of the EGCG curve was steeper than the 118-D-24 slope with a Hill-Slope of -2.  
3.2.10.3. Determining the effect of cefixime trihydrate and 
epigallocatechin gallate in the presence of reducing agents on 
strand transfer inhibition  
The effect of reducing agents such as DTT and B-Me was tested using the HIV-1 
IN ELISA when screening CEF and EGCG. The DTT concentration was 
increased to 10mM as opposed to the optimal 5mM DTT used in this ELISA. In 
addition, the effect of a weaker reducing agent than DTT, B-Me at 10mM, was 
tested when screening CEF and EGCG against HIV-1 IN. The comparison of ST 
inhibition attributed to CEF and EGCG in the presence of 5mM DTT, 10mM DTT 
and 10mM B-Me is depicted in Figure 3.31. An increase in IN ST inhibition was 
observed with an increase in DTT concentration when screening CEF and EGCG 
against HIV-1 IN. CEF demonstrated 53% in the presence of 10mM DTT 
whereas 66% IN ST inhibition was observed for EGCG. CEF and EGCG in the 
presence of 10mM B-Me yielded no appreciable activity against HIV-1 IN with 
16% and < 0% ST inhibition in comparison to the positive control. 
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Figure 3.31: The comparison of the activity of cefixime trihydrate (CEF) and epigallocatechin 
gallate (EGCG) against HIV-1 integrase (IN) in the presence of 5mM and 10mM DTT as well as 
10mM B-Me. The absorbance values measured at 620nm when conducting an HIV-1 IN ELISA 
was indicative of the activity of CEF and EGCG against HIV-1 IN. T-test analysis indicated that 
there were no significant differences between the positive controls obtained in the presence of the 
5mM DTT, 10mM DTT and 10mM B-Me (p > 0.005). The absorbance value of CEF in the presence 
of 10mM DTT and 10mM B-Me was significantly lower than the absorbance value of CEF in the 
presence of 5mM DTT (p = 0.0001). Although CEF in the presence of 10mM B-Me was significantly 
lower than CEF in the presence of 5mM DTT, it was not significantly lower than the positive control 
(10mM B-Me). EGCG in the presence of 10mM DTT was significantly lower than the positive 
control (10mM DTT) and the absorbance value of EGCG in the presence of 5mM DTT (p < 0.005). 
The error bars indicate the standard deviation of the average n = 3.  
 
3.3. Computational studies of cefixime trihydrate and 
epigallocatechin gallate 
3.3.1. Molecular docking of compounds with HIV-1 integrase 
3.3.1.1. Validating the docking protocol using control compounds 
To validate the ligand-receptor docking method, structurally-related INIs such as 
RAL, EVG and DTG were used in the docking studies since they have similar 
interactions with the HIV-1 IN active site. The best docking poses for RAL, EVG 
and DTG were selected based on their docking scores such as binding energy. 
Compounds with the lowest binding energy are deemed as the most favourable 
* 
* 
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receptor-ligand interactions.234 The binding energy for RAL, EVG and DTG were -
89.92 kilocalorie per mole (kCal/Mol), -39.89kCal/Mol and -54.45kCal/Mol, 
respectively. Figure 3.32 A illustrates the interaction of RAL with the defined 
active site of the HIV-1 IN with viral DNA. The hydroxyl group that forms part of 
the heteroatom triad of RAL forms a hydrogen bond with the side chain of the Glu 
152 residue that is present in the DDE motif of the IN active site (1.9Å). A 
secondary hydrogen bond is formed between an imine group (1) and the hydroxyl 
group of the threonine (Thr) 66 side chain (2.3Å). Furthermore, the lysine (Lys) 
159 residues present in the active site of IN formed two Pi interactions with the 
benzene ring (2) and the amine ring group (3) of RAL.  
EVG and DTG (Figure 3.32 B and C, respectively) interact with the active site 
mainly through a heteroatom triad as with RAL. The O (1) of the heteroatom 
oxygen triad of EVG forms two hydrogen bonds with the amino group on the side 
chain of asparagines (Asn) 144 (1.9Å) and with the imidazole group present on 
the side chain of histidine (His) 114 (2.1Å), respectively. A hydrogen bond 
interaction is observed between the amino group on the main chain of aspartic 
acid (Asp) 116 and the hydroxyl group (2) on EVG (2Å). In addition, charge 
interactions occur between the positively charged side chain of His 144 and the 
deprotonated O (3) of the carboxylic acid in the heteroatom oxygen triad (3.8Å). 
The interaction between DTG (Figure 3.32 C) and the IN monomer occurs via a 
hydrogen bond between the O (1) of the heteroatom oxygen triad present on 
DTG and the amino group on the side chain of Asn 144.
 Results 
 
60 
 
 
       
A              B       C 
Figure 3.32: Two-dimensional (2D) structural diagrams generated using Discovery Studio version 3.1 software, exemplify the 
interactions between the defined active site of the HIV-1 integrase (IN) and the control compounds A, B and C; raltegravir (RAL), 
elvitegravir (EVG) and dolutegravir (DTG), respectively. Residues involved in possible van der Waals interactions are represented as green 
circles. Pink and blue circles denote residues involved in hydrogen bonds, charge- and polar interactions, respectively. The blue arrows denote 
interactions between the HIV IN active site residues and the control compounds. The heteroatom oxygen triad is demarcated with red. The 
molecules on the compounds involved in interactions are denoted numerically.
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3.3.1.2. Molecular docking of cefixime trihydrate and epigallocatechin 
gallate with HIV-1 integrase  
Interactions between the defined HIV-1 IN active site and the HIT compounds identified 
when screening the NCC library were predicted via molecular modelling. CEF and 
EGCG were identified as INIs through SPA screening and their structures were 
subsequently obtained from www.nihclinicalcollection.com. Overall, 15 poses were 
successfully docked for CEF and 16 poses for EGCG through CDOCKER. These 
poses were ranked according to their binding energies and CDOCKER energies. Albeit 
many poses docked successfully, not all were favourable. The binding energy of CEF 
and EGCG were 183kCal/Mol and -74.57kCal/Mol, respectively. However, the 
CDOCKER scoring function rendered a more favourable result with CEF, -
439.55kCal/Mol as opposed to the CDOCKER energy of EGCG, -29.37kCal/Mol. The 
2D structures depicted in Figure 3.33 describe the interactions between the CEF (A) 
and EGCG (B) and the defined IN active site, respectively. Interactions between the 
residues in the IN active site and CEF mainly occur through hydrogen bonds within a 
3Å bond distance (Figure 3.33 A). The deprotonated carboxylic acid (1) forms two 
interactions with the aa residues of the IN active site: 1 - a hydrogen bond with the 
hydroxyl group on the side chain of the Asp 64 residue present in the IN active site 
(2.7Å) and 2 - charge interactions with the positively charged side chain of His 51 
(2.1Å). The highly reactive aromatic system is involved in the hydrogen bond 
interactions between the H31 of the amino group (2) attached to the amino-thiazoyl 
moiety and the carboxylic acid on the main chain of Thr 115 (2.1Å). The carboxylic acid 
on the main chain of Thr 115 forms an additional hydrogen bond with H36 that 
comprise the central imino group (3) (2.2Å). Furthermore, the deprotonated carboxylic 
acid at the terminal end of the chain (4) forms a hydrogen bond with the amino group 
on the side chain of glutamine (Gln) 148 (2.2Å). The O (5) of the carboxylic acid forms 
a hydrogen bond with the amino group on the side chain of Asn 144 (2.2Å). Figure 3.33 
B illustrates the interaction between the aa residues present in the IN active site and 
EGCG. The hydroxyl group (1) attached to the highly reactive benzopyran-diol interacts 
with the carboxylic acid on the main chain of leucine (Leu) 63 (2.3Å) via a hydrogen 
bond interaction. 
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A        B 
Figure 3.33: Two-dimensional (2D) structures demonstarting the predicted structural interactions between A - Cefixime trihydrate (CEF) 
and B - Epigallocatechin gallate (EGCG) and the defined HIV integrase (IN) active site. The 2D structural diagrams were constructed 
using the Discovery Studio version 3.1 receptor-ligand docking tool. All possible interacting amino acids (aa) of the active sites are 
indicated through the coloured circles. The pink and blue circles indicate the aa that are involved in possible hydrogen bonds, charge- or polar 
interactions, respectively. Aa residues with possible van der Waals interactions are represented by the green circles. The blue arrows denote 
possible bond formations between aa residues and the molecules comprising CEF and EGCG. The molecules of the compounds involved in 
interactions are numerically denoted.  
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3.3.2. Evaluation of the absorption and distribution properties of cefixime 
trihydrate and epigallocatechin gallate 
Osiris Property Explorer predicted the absorption, solubility and drug-like score of CEF 
and EGCG. Table 3.2 exhibit the predicted drug property values of CEF and EGCG. A 
good absorbed drug has a cLogP between -0.4 to 5.6 where CEF and EGCG exibited 
cLogP values < 5 thus indicating good absorption. The solubility of CEF and EGCG 
was -2.8 and -2.16, respectively, indicating moderate solubility of the compounds. LogS 
values greater than -4 are typically an indication of good solubility.  The drug-like 
scores of CEF and EGCG were 0.76 and 0.69, respectively. A drug-like score ranges 
from 0-1, where 1 indicates a good drug candidate while 0 indicates a poor drug 
candidate.  
Table 3.2: The predicted solubility, absorption and drug-like score of cefixime trihydrate and 
epigallocatechin gallate using Osiris Property Explorer. 
  Cefixime trihydrate Epigallocatechin gallate 
CLogP -0.65 2.65 
Solubility -2.8 -2.16 
Drug score 0.76 0.69 
 
In addition, absorption and distribution properties of CEF and EGCG were predicted 
using Discovery Studio version 3.1 software (Table 3.3). The predictive aqueous 
solubility model used predicts the solubility of compounds in water at 25°C which is 
expressed as logSw. The predicted logSw for CEF was -3.584 and the predicted logSw 
for EGCG was -6.104. These logSw values indicate that CEF is drug-like and highly 
soluble. The logSw value predicted for EGCG indicated that the drug-likeness of the 
compound was low but may still be soluble. The predicted HIA of CEF and EGCG were 
expressed according to their AlogP levels. Both compounds exerted an HIA level of 3 
with -2 ≥ AlogP98 ≥ 7. This indicates that CEF and EGCG are poorly absorbed after 
oral administration. The ADMET BBB model predicted the penetration of the 
compounds through the BBB after oral administration. The categorical BBB level of 
both CEF and EGCG were 4. This indicates that the BBB penetration predication of 
CEF and EGCG could not be defined because the compounds are not within the 99% 
confidence ellipse.  
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Table 3.3: The predicted human intestinal absorption, solubility and blood brain barrier penetration 
scores for the two HIT compounds obtained from Discovery Studio version 3.1 
  
Cefixime 
trihydrate 
Epigallocatechin 
gallate 
Human intestinal absorption 3 3 
Solubility -3.584 -6.104 
Blood brain barrier penetration 4 4 
 
The data obtained from Osiris Property Explorer and Discovery Studio version 3.1 was 
used to predict the oral bioavailability of CEF and EGCG using the Lipinski Ro5 
described in section 1.2.2.2. Data in Table 3.4 indicated that both CEF and EGCG do 
not fully adhere to these rules. 
Table 3.4: The predicted oral bioavailability of cefixime trihydrate and epigallocatechin gallate 
using Lipinski Rule of 5. 
  
Cefixime 
trihydrate 
Epigallocatechin 
gallate 
MW < 500 Daltons X √ 
cLogP < 5 √ √ 
Hydrogen bond donors < 5  √ X 
Hydrogen bond acceptors < 10 X X 
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The inevitable emergence of HIV-1 drug resistance mutations against the current 
antiretroviral agents has propagated investigations to identify novel antiretrovirals 
against enzymes and viral- or host proteins essential for HIV-1 replication. This 
study focuses on repurposing available drugs as HIV-1 INIs. By using 
recombinantly expressed HIV-1 INWT in an optimized SPA amended to an 
automated system, a small compound library, NCC, was screened to identify 
potential HIV-1 INIs. The expression and purification of HIV-1 INWT was confirmed 
through SDS-PAGE analysis as well as Western blot analysis. Binding and 
activity against the known INIs RAL, EVG and DTG confirmed that the purified 
recombinant IN was functional. Overall, two compounds were identified when 
screening the NCC compound library that yielded IN ST inhibition over 60%. 
These compounds were CEF and EGCG. Mutation studies indicated that the 
activity of CEF and EGCG were not affected by the viral IN mutations 
INQ148H/G140S. The binding mode of CEF and EGCG were predicted through 
molecular docking studies as well as through the screening of CEF derivatives. In 
silico studies indicated that CEF and EGCG were drug-like. The activity of CEF 
and EGCG could, however, not be confirmed through orthogonal assays. 
 
4.1. Successful expression and purification of HIV-1 subtype B 
integrase  
The HIV-1 NL4-3 IN sequence was cloned into pET15B which was subsequently 
transformed into E. coli BL21 (DE3) bacterial expression cells and induced with 
IPTG. SDS-PAGE gels indicated that the protein saliently expressed was HIV-1 
IN at approximately 32kDa.160 The His-tagged HIV-1 IN was purified through Ni-
affinity chromatography where the electron rich His-tag has a high affinity for the 
transitional metal, Ni2+. The single purification step has previously demonstrated 
protein purification of 95% expressed in E.coli 235 whereas the recombinant HIV-1 
IN in this study demonstrated 73% purity. Previous studies have indicated that 
the His-tag present on the recombinant HIV-1 IN did not affect the activity of the 
enzyme211 and therefore the His-tag was not cleaved in this study. Western blot 
analysis (Figure 3.16) confirmed the recombinant expression of HIV-1 IN with 
primary antibodies against the His-tag of the expressed HIV-1 IN as well as 
antibodies against the aa (23-34) sequence of HIV-1 IN. Additional bands were 
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observed at approximately 60kDa on a reducing SDS-PAGE gel which suggests 
dimerization of the HIV-1 IN enzyme.8,9 The Western blot analysis demonstrated 
an additional band higher than the prominently visible band when probed against 
the HIV-1 IN aa 23-34. However, the occurrence of dimerization on a reducing 
gel is unlikely since a reducing agent is added to perturb cysteine bonds involved 
in multimerization of HIV-1 IN enzymes. Since the additional band was also 
observed on a Western blot it can be assumed that dimerization may have 
occurred due to incomplete reduction of cysteine bonds. HIV-1 INWT is prone to 
aggregation and together with the fact that a high concentration of the protein 
was loaded on to the gel (75µM), the 5% B-ME used to reduce the protein may 
not have been sufficient. Parameters that influence dimer formation such as the 
reducing agent concentration, protein concentration and boiling duration of the 
sample can be tested. In addition, mass spectroscopy studies can be conducted 
to validate whether the additional band is indeed an HIV-1 IN dimer. Sufficient 
recombinant HIV-1 IN was expressed and purified for optimization of the SPA, 
the screening of the NCC compound library and HIV-1 IN ELISAs to minimize 
variability between experiments.  
4.2. The optimized SPA parameters 
In order to screen the NCC compound library, a suitable assay had to be 
developed that was able to screen multiple compounds simultaneously using an 
automated system. As described in section 1.2.3.5, the SPA was deemed the 
most suitable assay for this study and was therefore used to monitor IN ST 
activity. A protocol extracted from Grobler and co-workers203 was altered by 
modifying several variables in the assay such as buffer reagents, divalent metal 
cations, reducing agents and detergent concentrations which can compromise 
the efficacy of inhibitory compounds.236 The optimal conditions for the SPA were 
determined based on CPM signal, IN ST inhibition attributed to RAL and most 
importantly the Z-factor of the assay.  
Previous studies have demonstrated that the assembly of the IN viral DNA 
complex as well as 3’-end processing and IN ST requires a divalent metal cation, 
either Mg2+ or Mn2+, in order for it to exert its function.237,238 Although, Grobler and 
co-workers178 elucidated that Mg2+ was physiologically more relevant in vivo, 
Mn2+ is more compatible in in vitro experiments such as the SPA as IN activity is 
more robust in the presence of Mn2+.178 The Mg2+ was used in further SPA 
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experiments in this study, since this divalent metal cation is physiologically more 
relevant and RAL exerted a higher IN ST inhibition in the presence of Mg2+. 
In order to increase the CPM signal the stop solutions and buffer compositions 
were tested. When testing the buffer compositions, Buffer 4 (Chow199 buffer with 
100µg/ml BSA) demonstrated the highest CPM signal however the Z-factor was 
below zero which indicated that there was no separation band between the 
positive- and negative control and therefore the assay was deemed futile. This 
low Z-factor might be attributed to background signal indicating that the IN ST 
inhibition observed (70 ± 4.3%) when using Buffer 4 was possibly a false positive. 
For these reasons, Buffer 2 (Chow199) was used as the optimal assay buffer since 
this buffer demonstrated the second highest CPM signal (141 ± 49) and a 
marginal Z-factor of 0.4. However, the Z-factor indicated that the separation band 
between the positive-and negative control was low which suggested background 
signal. To further reduce background signal, various stop solutions were tested. 
Stop solution was added to the assay to terminate the enzymatic reaction and to 
float scintillation beads to the suface thus bringing the beads in closer proximity 
to the photomultiplier tube detectors thereby reducing background signal. EDTA 
at a final concentration of 62mM was found to be the optimal stop solution; likely 
due to the fact that EDTA is a Mg2+ chelator and therefore effectively terminated 
the activity of the enzyme. 
The fully optimised SPA was deemed an excellent assay with Z = 0.8 according 
to the screen assay quality category described by Zhang and co-workers.227 The 
assay was then further validated through dose-dependent studies of known 
controls. The SPA yielded IC50 values of 7.3 ± 0.3nM, 4.0 ± 1nM and 1.5 ± 0.8µM 
for RAL, EVG and 118-D24, respectively, which was statistically comparable (p > 
0.005) to the IC50 values previously documented in literature (described in section 
3.2.3). This then indicated that the optimised SPA was validated and could be 
used in subsequent HIV-1 IN activity screening experiments.  
In order to screen the entire NCC compound library, a SPA protocol analogous to 
the manual SPA protocol was amended to an automated system. The success of 
amending the manual SPA to an automated system was determined by 
comparing the IC50 values of RAL obtained from both the automated- and manual 
SPA. T-test analysis confirmed that the IC50 of RAL obtained when conducting 
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the manual SPA was statistically comparable (p = 0.99) to the IC50 of RAL when 
conducting the automated SPA indicating that this protocol was adequate for use 
on the automated system. The optimized SPA was used to screen the NCC 
compound library and subsequent compound derivative experiments. The SPA 
was then further used for mutant screening by replacing the HIV-1 INWT with the 
INQ148H/G140S. The SPA was validated by screening known controls such as RAL, 
EVG and DTG against the INQ148H/G140S mutant. Resistant profiles of RAL, EVG 
and DTG obtained through SPA screening against INQ148H/G140S correlated with 
previous reports as indicated in section 3.2.7 thus validating the SPA as a 
suitable assay for HIV-1 IN mutant screening. Since the INQ148H/G140S mutation 
decreased the activity of the enzyme, the concentration of the IN mutant was 
increased in order to increase the CPM signal that would yield a satisfactory Z-
factor. 
For mutation studies, the activity of the mutant IN, INQ148H/G140S, was tested and 
compared to the activity of INWT. The FCIC50 of INQ148H/G140S against control 
compounds was tested to determine the degree of resistance of the mutation. 
The activity of INQ148H decreased 6 fold when compared to the activity INWT which 
was in accordance with previous studies.229 The decrease in enzyme activity may 
be due to the INQ148H mutation that is present in the DDE motif of the HIV-1 IN 
active site and decreases the amount of viral DNA integrated into the host DNA 
consequently impairing the integration process.176 When pairing the primary 
mutation, INQ148H, with the secondary mutation, ING140S, the integration efficiency 
was restored and the activity of HIV-1 IN decreased by only 2 fold when 
compared to HIV-1 INWT. This data correlated with the results observed in the 
study conducted by Delelis and co-workers.229 
 
4.3. HITS identified when screening the NCC compound 
library 
This study focused on compounds exhibiting appreciable IN ST inhibition when 
screening the NCC compound library. Two compounds (out of a total of 727) that 
demonstrated IN ST inhibition > 60% were identified as a β-lactam antibiotic, 
CEF, and the Green Tea antioxidant, EGCG. Pooled compounds that contained a 
coloured compound within the group of compounds were considered false 
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positives. Due to quenching, these coloured compounds absorb the light emitted 
from the scintillant in the PVT SPA bead thereby decreasing the energy emitted. 
As such, these coloured samples appear to inhibit IN activity but may be artifacts. 
4.3.1. Cefixime trihydrate identified as a strand transfer inhibitor 
The notion of an antibiotic inhibiting the activity of a virus is uncommon, however, 
the β-lactam antibiotic, CEF, demonstrated IN ST inhibition with an IC50 = 6.0 ± 
1.2µM. CEF is a third generation cephalosporin antibiotic active against a wide 
range of gram-negative bacteria that is resistant to β-lactam antibiotics.239 CEF is 
renowned for its high affinity for its target, penicillin-binding protein (PBP) located 
in the bacterial cell wall that catalyses cell wall biosynthesis.240 The involvement 
of CEF in HIV antiretroviral activity has not been documented as yet, however 
cephalosporin oligonucleotides as well as monocyclic β-lactams have been 
reported as HIV PIs.241 To determine whether CEF was specific against HIV-1 IN, 
RT inhibition studies were conducted. CEF demonstrated no appreciable RT 
inhibition at both 10µM and 100µM which indicated that CEF may be specific to 
HIV-IN. Studies testing CEF against HIV-1 PR and other HIV-1 drug targets 
would confirm whether CEF is a specific HIV-1 IN inhibitor.  
4.3.2. The possible binding mechanism of cefixime trihydrate 
The activity of CEF against INQ148H/G140S was investigated since this mutation 
pathway is one of the main RAL resistance pathways. CEF maintained its activity 
against HIV-1 INQ148H/G140S (FCIC50 = 0.8) indicating that CEF does not share a 
genetic barrier with the RAL resistant mutation. This data suggests three 
theories: 1 - CEF may not bind to the active site of IN and its mechanism of 
action may differ from the mechanism of action of RAL and EVG, 2 - CEF may 
bind to viral DNA thereby disrupting the viral DNA-IN interaction which in turn 
interrupts the integration process, and 3 - CEF may influence the IN enzyme or 
the assay in a non-specific manner. Further studies to elucidate the mechanism 
of action of CEF against HIV-1 IN have to be conducted.  
Derivatives of CEF; 7-ACA, 7-ADCA and CSS were screened against HIV-1 IN to 
determine the moiety responsible for the HIV-1 IN ST inhibition. CSS, 7-ACA and 
7-ADCA are structurally related to CEF where a β-lactam ring structure attached 
to a dihydrothiazine ring is consistent throughout the structures of these 
compounds (Figure 3.25).242 Cephalosporin acylase hydrolyses cephalosporin C, 
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consequently producing 7-ACA and 7-ADCA which are intermediates in the 
production of semi-synthetic cephalosporin antibiotics such as CEF.243 No 
appreciable IN ST inhibition was observed with the CEF derivatives at 10µM and 
therefore it can be assumed that the β-lactam moiety alone is not responsible for 
the IN ST inhibition. AMP is a β-lactam antibiotic derived from penicillin and 
follows the same mechanism of action as CEF in preventing the synthesis of 
gram-negative and gram-positive bacterial cell wall.240 Both CEF and AMP 
possess β-lactam rings however they differ structurally where the dihydrothiazine 
ring on CEF is substituted with a thiazolidine ring on AMP. As such, the effect of 
AMP on IN ST activity was investigated. AMP demonstrated IN ST inhibition by 
66.5 ± 1.4%. Since our findings suggests that the β-lactam ring does not attribute 
to IN ST inhibition, inhibition may likely be due to interactions between the acyl 
side chain present on CEF and AMP or due to the terminal carboxylic acid group 
present on both CEF and AMP. 
Molecular modelling studies were conducted to predict the possible binding of 
CEF to the IN active site. RAL, EVG and DTG were docked into the modelled IN 
active site to validate the docking method. As described in literature, the 
coplanar, oxygen heteroatom triad was pivotal in the interaction with the IN active 
site and its subsequent chelation of Mg2+ (described in Section 3.3.2.1).244 
Molecular modelling data (depicted in Figure 3.33 A) demonstrated hydrogen 
bond interactions between the terminal carboxylic acid present on CEF and the 
Gln 148 residue attached to viral DNA. Since this carboxylic acid is present on 
both CEF and AMP, it can be conjectured that this moiety is responsible for IN ST 
inhibition as hypothesized above. However, the Gln 148 is attached to viral DNA 
indicating that CEF and AMP may disrupt the viral DNA-IN as previously 
mentioned. The theory of CEF as a DNA-binder is supported by the distinct 7-α-
iminomethoxycarboxy group of CEF that interacts via hydrogen bond interactions 
with the Thr 115 bound to viral DNA. CEF as a DNA binder has not been reported 
previously, and its mechanism of action solely relies on CEF binding to a 
transpeptidase enzyme. An additional hydrogen interaction was observed 
between CEF and the Asp 64 present in the DDE motif of the IN active site 
indicating that CEF might also perturb Mg2+. This predicted interaction is negated 
by resistant mutation profile results which suggested that CEF may not bind in 
the DDE motif of IN. The exact moiety responsible for IN ST inhibition is still 
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unclear however the predicted interactions and screening of CEF derivatives 
provide an insightful foundation. 
4.3.3.  In silico studies predicted that cefixime trihydrate is not drug-
like 
The focus of this study was to identify an INI through drug-repositioning as it 
would expedite the preclinical drug development phase since the compounds that 
were tested are in clinical trials or have already been FDA approved. CEF is an 
FDA approved drug used in bacterial infection treatment and as such it is 
expected to be drug-like. The drug-score of the compound was determined by 
evaluating the cLogP, aqueous solubility, MW and the overall drug-likeness of the 
compound. Prediction studies using Osiris Property Explorer exhibited a very low 
cLogP value (-0.65) which indicated high hydrophilicity. According to Osiris 
Property Explorer, a compound that is highly hydrophilic is easily absorbed, 
however, amendments to Lipinski Ro5 states that the cLogP of a compound 
should be between -0.4 and 5.6. Since the cLogP of CEF is not within the 
acceptable partition coefficient range, CEF is predicted as too hydrophilic and 
may not be able to cross the lipid membrane. CEF was predicted to be 
moderately soluble.  
A successful compound requires a solubility level that is concomitant with good 
absorption which is required for the systematic transportation of the compound. 
Discovery Studio software predictions confirmed that CEF is poorly absorbed 
after oral administration. Discovery Studio software utilises a model developed by 
Egan and co-workers245 that consists of a 182 compound training set. This 
training set includes 95% and 99% confidence ellipses generated by the 
ALogP98 and 2D polar surface area (2D_PSA) planes. Well-absorbed 
compounds are within these confidence ellipses where the absorption ability of 
compounds decreases outside the 95% ellipse. The absorption of CEF could not 
be predicted since CEF was not within the 95% confidence ellipse and was 
therefore deemed as a poor absorption compound.  
In addition, the oral bioavailability of CEF was predicted using Lipinski Ro5. By 
assessing the Lipinski Ro5 (Table 3.4), two of the four parameters were out of 
range (MW > 500 Daltons and hydrogen bond acceptors > 10) which indicated 
that CEF may be poorly absorbed or the permeability of the compound may be 
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low. Low MW of compounds are desirable in developmental stages of drugs 
since modifications during the developmental stages would likely result in an 
increase in MW. However, since CEF is an FDA approved drug where the MW > 
500 Daltons, it is likely that MW increased due to modifications during the 
development stages to optimize the drug-likeness of CEF. A high MW has been 
associated with low absorption, which corroborated the absorption prediction 
obtained using the Discovery Studio software and Osiris Property Explorer. In 
addition, in vivo testing of CEF confirmed the absorption predictions obtained 
through the Discovery Studio software which indicated that CEF is only 40-50% 
absorbed after oral absorption. Distribution studies in terms of BBB penetration 
after oral administration could not be determined because CEF was not within the 
99% confidence ellipse. This suggests that the ability of CEF to penetrate the 
BBB is low according to the BBB penetration criteria levels developed by Egan 
and Lauri.245 Therefore, through prediction studies, it can be concluded that CEF 
is not drug-like. 
4.3.4. Cefixime trihydrate was not active against integrase in 
orthogonal screening 
To validate whether CEF was a true IN ST inhibitor, it was screened in an 
orthogonal assay; the HIV-1 IN ELISA. CEF demonstrated no appreciable IN ST 
inhibition at 10µM and 100µM thereby contradicting the results obtained through 
the SPA. This was corroborated through HIV-1 phenotypic inhibition studies 
(Figure 3.29) suggesting that CEF does not directly inhibit IN activity. The 
discrepancy between the results obtained through SPA screening and the results 
obtained from the HIV-1 IN ELISA and phenotypic inhibition assay may be 
attributed to non-specific binding of CEF to IN when using the SPA. 
Cephalosporin C, that contains a β-lactam ring, has been reported as a non-
specific inhibitor against NADH dehydrogenase and murG enzymes when using a 
SPA.246 Cephalosporin C was considered a perturbing agent that causes enzyme 
inactivation. Since cephalosporin C and CEF are structurally related, CEF may 
perturb the IN enzyme in a similar manner and therefore CEF appeared to have 
inhibited IN activity. AMP inhibited IN ST reaction by 12% at 10µM and 51% at 
100µM, while the antiretroviral activity of AMP in the phenotypic inhibition assay 
was weaker but still apparent (51% IN ST inhibition at 200µM). The antiretroviral 
activity of AMP was not attributed to cytotoxic effects since AMP was not toxic at 
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the evaluated concentrations (section 3.2.9.1). This data indicate that AMP may 
play a role the inhibition of HIV-1 IN. The mechanism and binding mode of AMP 
to HIV-1 IN is yet to be elucidated.  
4.3.6. Epigallocatechin gallate is active against integrase and reverse 
transcriptase 
EGCG is potent antioxidant and forms part of the catechin group derived from 
Green Tea, Camillia sinensis.247 EGCG is the most abundant catechin in Green 
Tea and accounts for 50-80% of the catechin content.248 Previous studies have 
reported the involvement of EGCG in many therapeutic applications such as 
cancer, bacterial, viral- and fungal infections, diabetes, Parkinson’s disease, 
Alzheimer’s disease, stroke, inflammation, obesity and HIV.249–252 In 2011, EGCG 
phase 1 clinical trials in HIV-1 patients were initiated.253 The clinical trials were 
due for completion in July 2013 and the outcome thereof is still pending. 
(www.clinicaltrials.gov, accessed 1/10/2013). Interestingly, by independently 
screening the NCC compound library, EGCG was identified as IN ST inhibitor 
(6.0 ± 1.2µM). EGCG has been previously reported as an HIV-1 INSTI with IC50 = 
960nM.254 However, EGCG activity was not limited to IN where RT inhibition 
studies demonstrated that EGCG inhibited RT by 56% (Section 3.2.9.2). This 
result was expected since previous studies have reported that EGCG was active 
against several targets in the HIV-1 replication cycle such as the destruction of 
the virion, blocking of the gp120-CD4 interaction, as well as inhibition of HIV 
replication enzymes such as RT, PR and IN.254–257 
4.3.7. The galloyl moiety of epigallocatechin is involved in 
antiretroviral activity 
EGCG was tested against the HIV-1 mutant INQ148H/G140S and yielded a FCIC50 = 
0.06. This suggests that EGCG may bind to IN using a different binding site to 
which RAL binds as mentioned in section 4.3.2. The binding mechanism of action 
has not yet been defined however previous studies demonstrated that the galloyl 
moieties of catechins are pivotal in HIV-1 inhibition.254 EGCG is an ester of gallic 
acid and is comprised of a galloyl moiety (D ring) attached to a catechin 
backbone.258 Previous studies have reported that galloyl moieties are involved in 
HIV-1 IN ST inhibition as well as RT inhibition.233,254 According to Yang and co-
workers259, the electron rich polyphenolic structure of the galloyl moiety may 
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interact via hydrogen bond interactions with IN at a binding site that is still 
unknown.259 Molecular docking results in this study predicted that hydrogen bond 
interactions occurred between the hydroxyl group on the benzene ring of EGCG 
and the carboxylic acid group of Leu 68 in the catalytic core domain on IN. This 
predicted interaction suggests that EGCG may influence the activity of IN by 
binding to a residue within the active site of IN. The predicted interaction between 
EGCG and HIV-1 IN does not involve the galloyl moiety present on EGCG as 
identified through biological evaluation. This could be due to the stringent 
parameters used to dock the compound in the IN active site resulting in fewer 
poses docked or due to the active site on the prepared protein model that was 
not well defined. 
4.3.8.  Epigallocatechin gallate as a natural product is drug-like 
According to the Osiris Property Explorer predictions (Section 3.3.2), EGCG is a 
moderately soluble (-2.16) and well absorbed drug (2.6) and is therefore drug-like 
(0.69). As stated before, solubility of a compound is usually indicative of good 
absorption. However, Discovery Studio software predicted EGCG was a very low 
absorbed drug with a low solubility and therefore was not drug-like. The disparity 
between the solubility property and dug-likeness of EGCG obtained from Osiris 
property explorer and Discovery Studio may be due to the prediction models 
used. Osiris Property Explorer utilises the increment system that is based solely 
on atom type contributions, while Discovery Studio software utilises a predictive 
model that was generated using a training set comprising compound classes 
such as alkanes, alkenes, alkynes, halogens and amines to name a few.260 The 
Discovery studio software is more reliable than the Osiris property explorer since 
it does not include compounds that are not within the 99% and 95% confidence 
ellipse. As with CEF, the BBB penetration could not be predicted since the 
compound was not within the 95% and 99% confidence ellipsoids.  
By analysing EGCG according to Lipinski Ro5, EGCG does not fully adhere to 
the rules since the hydrogen bond acceptor is < 10 and hydrogen bond donor is < 
5. However, EGCG is a natural compound and therefore does not require 
stringent compliance to the Lipinski Ro5. Natural products have been de-
prioritized or in some cases eliminated from the drug discovery process due to 
the fact that some natural products do not comply to Lipinski Ro5 yet they can be 
excellent drugs.261 Although the Lipinski Ro5 may be evaded for natural products, 
 Discussion 
 
75 
 
a low LogP property should be maintained as natural products are more readily 
absorbed than synthetic compounds. The LogP value of EGCG predicted was not 
ideal however it complied with Lipinski Ro5 which states that the logP < 5. On the 
premise of the compliancy of the LogP value of EGCG with Lipinski Ro5, it can 
be assumed that EGCG is drug-like. 
4.3.9. DTT influences the activity of epigallocatechin gallate and 
cefixime trihydrate 
As with CEF, a secondary assay was conducted to confirm the HIV-1 IN ST 
inhibitory effect of EGCG. Results from the HIV-1 IN ELISA exhibited no 
appreciable IN ST inhibition (Figure 3.28). It was evident that there was a 
component present in the SPA experiment that influenced the behaviour of both 
EGCG and CEF (Section 4.3.2) since both of these compounds did not evoke 
appreciable activity against HIV-1 IN in an orthogonal assay. Following this 
observation, it was then hypothesised that DTT in the presence of EGCG and 
CEF played a role in HIV-1 IN activity. Subsequently, DTT was used as a 
reducing agent in both biological assays to enhance IN activity in vitro by 
inhibiting the oxidation of free sulfhydryl residues. The concentration of DTT 
differed between the two biological assays where the HIV-1 IN ELISA reaction 
buffer contained 5mM DTT and the SPA reaction buffer contained 10mM DTT. 
The DTT concentration was increased to 10mM in the HIV-1 IN ELISA to 
determine whether this variable would influence the effect of EGCG and CEF on 
HIV-1 IN activity. A weaker reducing agent, B-Me (10mM), was used as an 
additional parameter to confirm whether an increased reducing agent 
concentration or the reducing agent itself had an influence on the behaviour of 
EGCG and CEF. The reducing agent, DTT at a high concentration, has 
previously been reported to weaken interactions between HIV-1 IN monomers.262 
EGCG and CEF in the presence of 10mM DTT yielded higher IN ST inhibition 
while EGCG and CEF in the presence of 10mM B-Me exerted no appreciable IN 
ST inhibition. This data suggests that EGCG and CEF in the presence of an 
increased DTT concentration inhibit IN ST. The controls (negative, positive and 
RAL) in the presence of 10mM DTT and 10mM B-ME were not significantly 
different (p > 0.05) from the controls in the presence of 5mM DTT (Figure 3.31). 
This indicated that an increased DTT concentration only affected the activity of 
HIV-1 IN in the presence of EGCG and CEF.  
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Studies have reported that a high concentration of DTT disrupts IN dimers where 
the thiol groups of DTT targets the CCD of IN and therefore decrease the activity 
of IN.262 DTT at a higher concentration may interact with EGCG and CEF in such 
a manner that enables the compounds to more efficiently disrupt IN dimers. B-ME 
is considered a weaker reducing agent than DTT because B-ME only comprises 
one thiol group whereas DTT comprise two thiol groups. Since thiol groups play a 
vital role in IN dimer disruptions, the weaker B-Me did not interrupt IN monomer 
interactions and therefore no appreciable IN ST inhibition was observed.262,263 
Altogether, the discrepancy between the results obtained from the SPA and the 
HIV-1 IN ELISA may be attributed to the DTT concentration difference.  
4.3.10. Epigallocatechin gallate is auto-oxidized at pH levels 
above 7 
Since EGCG activity could not be validated through an HIV-1 IN ELISA (Section 
4.3.9), the activity of EGCG was investigated in HIV infected mammalian cells. 
An EC50 = 23.5 ± 2µM was observed however cytotoxicity results indicated that 
EGCG was toxic to MT-4 cells within this concentration range (Figure 3.26). This 
suggests that the antiretroviral activity caused by EGCG may be attributed to 
cytotoxicity. According to previous reports, polyphenolic compounds such as 
EGCG are susceptible to auto-oxidation in cell culture medium such as DMEM 
and RPMI 1640 due to the pH of the cell culture medium (pH 7.2).264–266 Hou and 
co-workers267 proposed a possible mechanism of action of the auto-oxidation of 
EGCG. When EGCG undergoes auto-oxidation, it consumes O2 consequently 
producing superoxide (•O2
-) and EGCG radicals (•EGCG). The •O2
- is converted 
to H2O2 and •O2
- and in the presence of metal ions, unpaired electrons binds to 
EGCG and is localized at the B ring thus forming •EGCG and H2O2. The •EGCG 
reacts with another •EGCG producing an EGCG dimer and •O2
-. The EGCG 
dimers can be further oxidized consequently forming other compounds. Due to 
the extracellular H2O2 produced when EGCG undergoes auto-oxidation, the cells 
may have encountered oxidative stress leading to cell death.268 
4.4. Conclusion 
Overall, 727 compounds in the NCC compound library were screened with the 
aim of repositioning existing drugs as INIs. CEF and EGCG were identified as INI 
through SPA screening and were therefore further investigated. Computational 
studies confirmed the drug-like properties of CEF and EGCG as indicated by 
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previous studies. Molecular modelling studies predicted that CEF and EGCG 
interacted with HIV-1 IN via hydrogen bond interactions. No cross-resistance of 
CEF and EGCG was observed with RAL viral mutations which indicated that 
these compounds do not share a binding mechanism of action with RAL. 
Orthogonal screening indicated that the activity of both CEF and EGCG was 
dependent on the DTT concentration. The IN ST inhibitory effect of CEF was not 
significant in in vitro phenotypic inhibition screening and therefore it can be 
concluded that CEF was an IN dimer disruptor in the presence of 10mM DTT. 
Meanwhile, the antiretroviral effect of EGCG on HIV could not be validated since 
EGCG demonstrated cytotoxicity. This study could not validate whether EGCG 
was a true INI however, our results corroborate the findings from previous studies 
showing that EGCG is an INI with an unknown mechanism of action. 
4.5. Future studies 
The findings from the present study can be advanced by conducting experiments 
for: 
1) Generating a quench curve on the scintillation counter in order to screen the 
remaining NCC compounds that posses colour as potential INSTIs. 
2) Evaluating the resistance mutation profiles of CEF and EGCG against the 
remaining RAL resistance pathways (N155H, N155H/E92Q or T97A, 
Y143C/R, Y143C/R coupled with T97A) to determine whether IN mutations 
responsible for resistance to RAL confer cross resistance to CEF and EGCG. 
3) Further optimization of the manual SPA to evade the identification of non-
specific HITS. 
4) Conducting dimerization assays to determine the multimerization of IN in the 
presence of EGCG and CEF with a range of DTT concentrations. 
5) Identifying the structural moieties of CEF, AMP and EGCG involved in IN 
binding as well as the residues to which these compounds bind and the 
subsequent mechanism of action. 
6) Screening CEF against other HIV-1 drug targets to determine whether CEF is 
specific to IN.  
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